2022年11月, 日本放射線腫瘍学会, 2022年優秀教育講演賞　　　　　　　　　　　　　　　
頭頸部IMRT

2017年04月, 日本医学放射線学会, Bronze Medal (Cypos award)　　　　　　　　　　　　　　　
Treatment outcome after Radiation Therapy for Mucosal Malignant Melanoma of Head and Neck
安田 耕一

2014年12月, 日本放射線腫瘍学会, 第20回 梅垣賞　　　　　　　　　　　　　　　
[18F]fluoromisonidazole and a New PET System With Semiconductor Detectors and a Depth of Interaction System for Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer
安田 耕一

2013年04月, 日本医学放射線学会, Silver Medal (Cypos award)　　　　　　　　　　　　　　　
照射前FMISO-PETの集積部位と照射後再発の位置関係
安田 耕一

Feasibility Study of Multiorgan Dosiomics for Evaluating Radiation-Induced Xerostomia and Dysphagia in Head and Neck Cancer Radiotherapy
Takahiro Nakamoto, Koichi Yasuda, Takaaki Yoshimura, Takahiro Kanehira, Hiroshi Tamura, Sora Takagi, Sora Kobayashi, Tomohiko Miyazaki, Shuhei Takahashi, Yoshihiro Fujita, Takayuki Hashimoto, Hidefumi Aoyama
Cancers, 18, 4, 619, 619, MDPI AG, 2026年02月13日
研究論文（学術雑誌）, Background/Objectives: The severity of radiation-induced toxicity in head and neck cancer (HNC) radiotherapy should be predicted for the prognosis of the patient’s quality of life. Multiple organs at risk (OARs) are susceptible to toxicity in the head and neck. Hence, we aimed to investigate the feasibility of evaluating radiation-induced xerostomia and dysphagia based on multi-OAR dosiomics in HNC radiotherapy. Methods: We used radiotherapy treatment planning and toxicity data collected from 44 patients with HNC. High- and low-toxicity grades were classified using dosiomic models derived from multiple OARs. Dosiomic features were computed from the planned dose distribution per OAR. A prediction model was derived using selected dosiomic features and toxicity grades based on extreme gradient boosting for every OAR and all OARs. The model performance was evaluated in terms of the area under the curve (AUC) from leave-one-out cross-validation. Models based on dose volume histogram features and combining these with dosiomic features were derived to compare the prediction performance per OAR. Performance comparisons across OARs were also conducted. Results: The prediction models with the highest AUCs for xerostomia and dysphagia were the dosiomic model using all OARs, with an AUC of 0.843 (95% confidence interval—CI, 0.725–0.961), and that using the middle pharyngeal constrictor muscle, with an AUC of 0.878 (95% CI, 0.772–0.984). Conclusions: The evaluation results demonstrated the feasibility and potential of predicting radiation-induced toxicities based on multi-OAR dosiomics in HNC radiotherapy. Further investigations are required to determine the generalizability of our findings.

Effect of Mouthpiece Materials for Proton Therapy of Head and Neck Cancer With an Investigation of Material Suitability
Masaaki Suzuka, Takashi Mori, Shigeru Yamano, Akiko Takeuchi, Tomoka Shima, Koichi Yasuda, Yurika Kinoshita, Keiji Nakazato, Hideki Minatogawa, Yasuhiro Dekura, Masayoshi Tomita, Hidefumi Aoyama, Kazuyuki Minowa
Oral Science International, 23, 2, Wiley, 2026年02月11日
研究論文（学術雑誌）, ABSTRACT

Aim

To investigate the effect and suitability of mouthpiece materials for proton therapy (PT) of head and neck cancer (HNC).

Methods

Computed tomography (CT) numbers and the stopping power ratios (SPRs) of six dental materials were measured. The SPRs were converted to CT numbers, and the materials with the highest, lowest, and closest to the CT numbers of surrounding normal tissue were identified. To investigate how mouthpiece CT numbers affect the dose distribution for HNC, treatment plans of 17 patients were recalculated by changing the mouthpiece CT numbers to these three CT numbers, and doses to normal tissues were measured.

Results

Vinyl polysiloxane had the highest CT number, and thermoplastic ethylene vinyl acetate copolymer splints had the lowest CT number. Temporary relining resin had the CT number closest to normal tissue. Temporary relining resin had the smallest difference in the CT of the CT image, and the CT converted from SPR. The plans of temporary relining resin did not differ significantly from the actual plan, and the patient with the largest dose difference had a 1.75 gray equivalent (GyE) in the mandible max dose. However, that of vinyl polysiloxane and that of thermoplastic ethylene vinyl acetate copolymer splints differed significantly from the actual plans in several of the measured items, with the maximum difference of 5.43 GyE in the oral mean dose.

Conclusion

We confirmed that changing the material of the mouthpiece could cause the dose to normal tissues to vary by approximately 5 GyE.

Sclerosing rhabdomyosarcoma of the infratemporal fossa in an adult: A favorable long-term outcome
Chikako Yura, Wataru Kakuguchi, Naohiro Ogawa, Daigo Matsuyama, Shin Ariga, Koichi Yasuda, Taku Maeda, Aya Yanagawa-Matsuda, Yuichi Ashikaga, Yoichi Ohiro
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 38, 1, 82, 87, Elsevier BV, 2026年01月
研究論文（学術雑誌）

Summary of Japanese clinical practice guidelines for head and neck cancer - 2025 update edited by the Japan Society for Head and Neck Cancer.
Nobuhiro Hanai, Mizuo Ando, Hiroto Ishiki, Nobuhiro Ueda, Susumu Okano, Isaku Okamoto, Hiroyuki Ozawa, Satoshi Kano, Tomonori Kanda, Yuki Saito, Hirotaka Shinomiya, Keisuke Takanari, Toshifumi Tomioka, Hiroshi Fuseya, Yoshitaka Honma, Atsushi Motegi, Koichi Yasuda, Takeshi Kodaira, Hiroshi Kurita, Ken-Ichi Nibu, Seiichi Yoshimoto, Akihiro Homma
Auris, nasus, larynx, 52, 6, 709, 724, 2025年10月21日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2025 Edition were developed to provide clear evidence-based recommendations that reflect recent advancements and evolving clinical needs in head and neck cancer care. Advances in immunotherapy, targeted therapies, surgical techniques, and genomic medicine have expanded treatment options and added new complexities. This edition offers practical, up-to-date guidance to support consistent decision making across diverse clinical scenarios. Compared with the 2022 edition, the guidelines have been substantially expanded to 63 clinical questions (CQs) across 14 categories. A new feature is the inclusion of commentary columns that address clinically important topics not suited to the CQ format, such as special patient populations, novel therapies, and rare malignancies. To reflect the growing role of precision oncology, updated recommendations for molecular-targeted treatments have been added based on specific genomic alterations, in alignment with the current approvals in Japan. While maintaining the structure of previous editions, this edition addresses the changing clinical environment while also helping to inform future discussions and directions in head and neck cancer care.

Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.
Ling-Long Tang, Cheng-Long Huang, Shao-Jun Lin, Quynh-Thu Le, Brian O'Sullivan, Sue S Yom, Shao Hui Huang, Annie W Chan, Nancy Lee, Jian-Ji Pan, Michael Benedict A Mejia, Yong Chan Ahn, Kenneth C W Wong, Lachlan McDowell, Ester Orlandi, Jeppe Friborg, Yu-Pei Chen, Koichi Yasuda, Takeshi Kodaira, Alexander C Whitley, Ann D King, Gregorius Ben Prajogi, Ezra Hahn, Jin-Ching Lin, Naomi Kiyota, Victor Lee, Peng-Jie Ji, Ying Hitchcock, Frank Hoebers, Pierre Blanchard, Sung Ho Moon, Wan Zamaniah Wan Ishak, Kevin J Harrington, Kun-Yu Yang, A Dimitrios Colevas, Anna Lee, Chao-Su Hu, David Rosenthal, Farzan Siddiqui, Johannes Albertus Langendijk, Jin-Yi Lang, Jun-Lin Yi, Liang-Fang Shen, Ji-Bin Li, Li-Zhi Liu, Anne W M Lee, Hai-Qiang Mai, Ming-Kai Yang, Ying Sun, Melvin L K Chua, Jun Ma
The Lancet. Oncology, 26, 9, e477-e487, 2025年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology jointly developed evidence-based guidelines and a contouring atlas for primary target volume delineation for radiotherapy in nasopharyngeal carcinoma. The guidelines systematically address three crucial challenges: margin design of clinical target volumes; target volume delineation after induction chemotherapy; and low-risk clinical target volume delineation based on local stepwise extension patterns. Based on a comprehensive systematic review and critical appraisal by an international multidisciplinary panel of 50 nasopharyngeal carcinoma specialists from 17 countries and regions, these guidelines are in keeping with advances in nasopharyngeal carcinoma diagnosis and treatment, embodying contemporary treatment concepts, and elaborating on the differences in practice. These guidelines aim to support global clinical practice in radiotherapy target volume delineation, substantially enhancing homogeneity and reducing variability in nasopharyngeal carcinoma target delineation.

Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.
Ling-Long Tang, Cheng-Long Huang, Shao-Jun Lin, Quynh-Thu Le, Brian O'Sullivan, Sue S Yom, Shao Hui Huang, Annie W Chan, Nancy Lee, Jian-Ji Pan, Michael Benedict A Mejia, Yong Chan Ahn, Kenneth C W Wong, Lachlan McDowell, Ester Orlandi, Jeppe Friborg, Yu-Pei Chen, Koichi Yasuda, Takeshi Kodaira, Alexander C Whitley, Ann D King, Gregorius Ben Prajogi, Ezra Hahn, Jin-Ching Lin, Naomi Kiyota, Victor Lee, Peng-Jie Ji, Ying Hitchcock, Frank Hoebers, Pierre Blanchard, Sung Ho Moon, Wan Zamaniah Wan Ishak, Kevin J Harrington, Kun-Yu Yang, A Dimitrios Colevas, Anna Lee, Chao-Su Hu, David Rosenthal, Farzan Siddiqui, Johannes Albertus Langendijk, Jin-Yi Lang, Jun-Lin Yi, Liang-Fang Shen, Ji-Bin Li, Li-Zhi Liu, Anne W M Lee, Hai-Qiang Mai, Ming-Kai Yang, Ying Sun, Melvin L K Chua, Jun Ma
The Lancet. Oncology, 26, 9, e488-e498, 2025年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The Chinese Society for Therapeutic Radiology Oncology, the Chinese Anti-Cancer Association, the Chinese Society of Clinical Oncology, the Head and Neck Cancer International Group, the European Society for Radiotherapy and Oncology, and the American Society for Radiation Oncology collaboratively developed evidence-based guidelines and a comprehensive contouring atlas for neck target volume delineation in nasopharyngeal carcinoma. These guidelines address five key challenges in modern radiotherapy practice: margin design of clinical target volume; nodal target volume delineation after induction chemotherapy; delineation of equivocal nodes evident on imaging; low-risk clinical target volume delineation based on regional stepwise extension patterns; and modifications for anatomical boundaries of lymphatic areas. Developed through a rigorous systematic review and expert appraisal process by a panel of 50 international, multidisciplinary members from 17 countries and regions, these guidelines incorporate the latest advances in nasopharyngeal carcinoma diagnosis and treatment. They reflect contemporary therapeutic concepts and elaborate on current practice variations. These guidelines aim to standardise global practice, substantially improving consistency and reducing variability in nasopharyngeal carcinoma radiotherapy target delineation.

Mathematical mechanistic model representing the cancer immunity cycle under radiation effects.
Taisuke Takayanagi, Koichi Miyazaki, Kana Yamasaki, Takahiro Yamada, Futaro Ebina, Takahiro Kanehira, Yasuhito Onodera, Keiji Kobashi, Hiroshi Taguchi, Koichi Yasuda, Norio Katoh, Takayuki Hashimoto, Hidefumi Aoyama, Hiroki Shirato, Kenji Chamoto
Scientific reports, 15, 1, 19940, 19940, 2025年06月06日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Combining radiotherapy with immune checkpoint inhibitors is a promising approach to improve the effectiveness of cancer treatment. However, the success rates of these clinical studies are limited. It is essential to determine the optimal irradiation scheme that maximizes the therapeutic effect by taking into account the balance between the positive and negative effects of radiation on immunity. In this context, we developed a mathematical mechanistic model that simulates (1) the balance between effector and exhausted cytotoxic T-lymphocytes (CTLs), (2) the number of neoantigens released by high-dose irradiation, and (3) the impact of radiation on draining lymph nodes (DLNs) for systemic anti-tumor immunity, and tested whether this mathematic model fits in several animal experiments. Our mechanistic model reproduced the anti-tumor effects of several cancer treatment models for combination therapies with radiation, immune checkpoint inhibitors, and/or a metabolic modulator. Furthermore, this mechanistic model simulated that tumor suppression in distant metastatic foci, known as the abscopal effect, was dysregulated by hypofractionated high-dose irradiation or by the direct radiation exposure on DLN. The mechanistic model successfully reproduced tumor control under various treatment conditions with appropriate parameters, indicating that it may be useful for optimizing immunoradiotherapy prescriptions.

鼻副鼻腔悪性腫瘍放射線治療後の晩期障害:放射線治療の種類による違いについて　　　　　　　　　　　　　　　
安田 耕一, 高橋 周平, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 木下 留美子, 加納 里志, 本間 明宏
頭頸部癌, 51, 2, 178, 178, (一社)日本頭頸部癌学会, 2025年05月
日本語

Improved local control and survival outcomes with RADPLAT in T4 oropharyngeal cancer: a retrospective study
Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Hiroshi Idogawa, Ryohei Katsumata, Koichi Yasuda, Naoya Kinota, Koji Yamasaki, Yasushi Shimizu, Jun Taguchi, Hidefumi Aoyama, Akihiro Homma
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025年03月27日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）

Multicentric Cross-Sectional Survey to Assess the Variation of Fractionation Strategies Used in the Management of Head and Neck Cancers in the Asian Region (INNOCENCE-ASIA).
Ajeet Kumar Gandhi, Supriya Chopra, Madhup Rastogi, Indranil Mallick, Misael C Cruz, Koichi Yasuda, Ying Ying Sum, Yasushi Nagata, Hong-Gyun Wu, Gregorius B Prajogi, Henry Kodrat, Mingwei Ma, Asif Nisar, Imjai Chitapanarux
JCO global oncology, 11, e2400349, 2025年01月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: Head and neck cancers (HNCs) are in general treated with conventional fractionation regimen of 1.8-2 Gy per fraction. Altered fractionation (ALFT) strategies such as hypofractionation radiotherapy (HYPO-RT), accelerated fractionation radiotherapy (AFRT), and hyperfractionation radiotherapy (HFRT) have not been practiced uniformly across centers in different parts of the world. Countries in Asia share common cancer demographics, and we designed this survey for Federation of Asian Radiation Oncology (FARO) member countries to understand the usage and challenges in the delivery of ALFT in HNCs. MATERIALS AND METHODS: A 21-point electronic survey (Federation of Asian Radiation Oncology Research Network [FERN]-S-005) was designed by the FERN and was circulated through the FARO research secretariat to the FARO council member countries and the responses were collected between August and November 2023. RESULTS: Twelve of 14 member countries (85.7%) responded to the survey. Twenty-seven responses were received and 78% of the respondents belonged to government/teaching academic institute. 4/27 (14.8%) reported never using HYPO-RT for any of the clinical subsite of HNCs, while the majority (85.2%) used it for glottic cancers and 22% also used it for postoperative setting. Majority (77.7%) used a fractionation schedule with dose per fraction ranging between 2.2 and 2.5 Gy. 6/27 (22.2%) used AFRT for definitive setting and five of these also used concurrent chemoradiotherapy. 4/27 (14.8%) centers reported using HFRT. The most common reason (62.9%) for the limited usage of AFRT/HFRT was reported to be logistical, such as unavailability of machine slots, patient load, and so on. CONCLUSION: The result of the survey suggests that among the ALFT strategies for HNCs, HYPO-RT schedules have common interest and feasibility among the FARO member countries and also highlights the challenges in the delivery of AFRT/HFRT in the Asian region.

Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy
Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Manami Otsuka, Rikiya Takashina, Hideki Minatogawa, Hajime Higaki, Yusuke Uchinami, Hiroshi Taguchi, Kentaro Nishioka, Koichi Yasuda, Naoki Miyamoto, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Physics and Imaging in Radiation Oncology, 100690, 100690, Elsevier BV, 2024年12月, ［査読有り］
研究論文（学術雑誌）

Uptake of ultra-hypofractionated radiation therapy following breast-conserving surgery among patients with early-stage breast cancer: a multi-institutional questionnaire survey.
Haruka Uezono, Tsuyoshi Onoe, Naoto Shikama, Yuka Ono, Hidenari Hirata, Yoshinori Ito, Koichi Yasuda, Nobuki Imano, Koyo Kikuchi, Tairo Kashihara, Terufumi Kawamoto, Naoki Nakamura
Breast cancer (Tokyo, Japan), 2024年07月24日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: In patients with early-stage breast cancer following breast surgery, ultra-hypofractionated (UHF) breast/chest wall radiation therapy (RT) has been shown to be non-inferior to a moderate-hypofractionated (MHF) regimen, with a minimal risk of breast induration, in the FAST-Forward trial, and UHF is now becoming the standard regimen in Europe. Herein, we aimed to investigate Japanese patients' attitudes toward the UHF regimen. METHODS: A questionnaire-based survey was conducted at 13 RT centers in nine prefectures across Japan. All patients underwent breast-conserving surgery, followed by either conventional fractionation (2 Gy/fr) or MHF (2.66 Gy/fr) whole-breast irradiation (WBI) with or without a tumor bed boost. The questionnaire consisted of 13 questions mainly addressing quality-of-life during RT. Key questions included an 11-point scale (0-10) for rating the patients' enthusiasm for the UHF regimen and prioritization of the following treatment-related effects: treatment efficacy, acute/late adverse effects, physical/emotional/financial burden, and breast cosmesis. The patient and treatment characteristics were assessed by a physician. RESULTS: In total, 247 questionnaires were administered between November 2022 and June 2023. The age distribution was as follows: < 50:50 s:60 s: ≥ 70 = 59 (24%):76 (30%):63 (26%):49 (20%). Sixty-nine percent of patients rated their enthusiasm for the UHF regimen at ≥ 6 out of 10 points (45% rated 10/10). Treatment efficacy was the highest priority for most patients (89%), whereas breast cosmesis the lowest priority (53%). CONCLUSIONS: Patients' enthusiasm for UHF-WBI was observed across the cohort. These results could motivate researchers and clinicians to introduce UHF regimens in clinical practice.

A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.
Kentaro Nishioka, Takayuki Hashimoto, Takashi Mori, Yusuke Uchinami, Rumiko Kinoshita, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Yoichi M Ito, Seishin Takao, Masaya Tamura, Taeko Matsuura, Shinichi Shimizu, Hiroki Shirato, Hidefumi Aoyama
Advances in radiation oncology, 9, 5, 101464, 101464, 2024年05月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer. METHODS AND MATERIALS: Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE. RESULTS: Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%). CONCLUSIONS: The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies.

Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization.
Takaaki Yoshimura, Ryota Yamada, Rumiko Kinoshita, Taeko Matsuura, Takahiro Kanehira, Hiroshi Tamura, Kentaro Nishioka, Koichi Yasuda, Hiroshi Taguchi, Norio Katoh, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama
Journal of radiation research, 2024年03月17日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10-1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10-1 in IMXT; 0.04, 0.74 and 0.19 × 10-1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10-1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy.

Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama
Radiation oncology journal, 42, 1, 74, 82, 2024年03月, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival. RESULTS: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541). CONCLUSION: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.

Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group.
Koichi Yasuda, Naomi Kiyota, Kazuto Matsuura, Satoshi Saito, Yoshitaka Honma, Yoshinori Imamura, Kaoru Tanaka, Sadamoto Zenda, Takuma Onoe, Takeshi Kodaira, Satoshi Kobayashi, Hidefumi Aoyama, Nobuhiro Hanai, Akihiro Homma
Frontiers in oncology, 14, 1441056, 1441056, 2024年, ［査読有り］, ［筆頭著者］, ［国際誌］
英語, 研究論文（学術雑誌）, INTRODUCTION: Chemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications. METHODS: In April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions. RESULTS: The major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65-74 years with PS 0-1 and 65-74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50. DISCUSSION: In Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients.

Clinical outcomes for olfactory neuroblastoma.
Akira Nakazono, Hiroaki Motegi, Masanobu Suzuki, Yuji Nakamaru, Shigeru Yamaguchi, Yukitomo Ishi, Satoshi Kano, Nayuta Tsushima, Aya Honma, Takayoshi Suzuki, Shogo Kimura, Seijiro Hamada, Jun Taguchi, Yasushi Shimizu, Takashi Mori, Koichi Yasuda, Hidefumi Aoyama, Ichiro Kinoshita, Miki Fujimura, Akihiro Homma
Frontiers in oncology, 14, 1329572, 1329572, 2024年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Olfactory neuroblastoma (ONB) is a rare malignant tumor arising from the olfactory neuroepithelium. The standard of care for ONB is surgical resection; however, detailed treatment protocols vary by institution. Our treatment protocol consists of endoscopic skull base surgery (ESBS) for endoscopically resectable cases and induction chemotherapy followed by craniotomy combined with ESBS for locally advanced cases, with postoperative radiotherapy performed for all cases. Chemoradiotherapy (CRT) is performed in unresectable cases. In this study, we evaluate our treatment protocol and outcomes for ONB. METHODS: A retrospective review of patients with ONB was conducted. Outcomes included survival outcomes and perioperative data. RESULTS: Fifteen patients (53.6%) underwent ESBS, 12 (42.9%) underwent craniotomy combined with ESBS, and 1 (3.6%) received CRT. The 5- and 10-year overall survival rates for all patients were 92.9% and 82.5%, respectively, with a median follow-up period of 81 months. The 5- and 10-year disease-free survival rates were 77.3% and 70.3%, respectively, and the 5- and 10-year local control rates were 88.2% and 80.2%, respectively. Patients undergoing ESBS demonstrated a significantly shorter operating time, period from operation to ambulation, hospitalization period, and less blood loss than those undergoing craniotomy combined with ESBS. CONCLUSION: Our treatment protocol was found to afford favorable outcomes. Patients who underwent endoscopic resection showed lower complication rates and better perioperative data than those who underwent craniotomy combined with ESBS. With appropriate case selection, ESBS is considered a useful approach for ONB.

Radiotherapy with or without chemotherapy for locally advanced head and neck cancer in elderly patients: analysis of the Head and Neck Cancer Registry of Japan.
Koichi Yasuda, Yusuke Uchinami, Satoshi Kano, Jun Taguchi, Daisuke Kawakita, Megumi Kitayama, Kentaro Nishioka, Takashi Mori, Fuki Koizumi, Yuri Fujii, Yasushi Shimizu, Keiji Kobashi, Seiichi Yoshimoto, Ken-Ichi Nibu, Akihiro Homma, Hidefumi Aoyama
International journal of clinical oncology, 2023年12月29日, ［査読有り］, ［筆頭著者, 責任著者］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Whether concurrent chemotherapy with radiotherapy (CRT) is effective for elderly patients with head and neck cancer is a controversial topic. This study aimed to analyze the effectiveness of CRT vs. radiation therapy (RT) among elderly patients in Japan. METHODS: Data from the Head and Neck Cancer Registry of Japan were extracted and analyzed. Patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx who received definitive CRT or RT between 2011 and 2014 were included. RESULTS: CRT was administered to 78% of the 1057 patients aged ≥ 70 years and 67% of the 555 patients aged ≥ 75 years. For the patients aged ≥ 75 years, the overall survival (OS) rate was significantly better in the CRT group than in the RT group (P < 0.05), while the progression-free survival (PFS) rate was not significantly different (P > 0.05). The add-on effect of CRT was significantly poor in elderly patients (P < 0.05), and it was not a significant factor in the multivariate analysis for patients aged ≥ 75 years. After propensity score matching, there were no significant differences in the OS and PFS rates between the patients aged ≥ 70 years and those aged ≥ 75 years (all, P > 0.05). CONCLUSION: Although aggressive CRT is administered to elderly patients in Japan, its effectiveness is uncertain. Further prospective randomized trials are needed to verify whether CRT is superior to RT alone for elderly patients.

Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma.
Yusuke Uchinami, Koichi Yasuda, Satoshi Kano, Manami Otsuka, Seijiro Hamada, Takayoshi Suzuki, Nayuta Tsushima, Shuhei Takahashi, Yoshihiro Fujita, Tomohiko Miyazaki, Hajime Higaki, Jun Taguchi, Yasushi Shimizu, Tomohiro Sakashita, Akihiro Homma, Hidefumi Aoyama
Discover. Oncology, 14, 1, 226, 226, 2023年12月08日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Tri-weekly cisplatin and radiotherapy (CDDP + RT) is a standard of care for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) but is sometimes challenging to complete in older patients. Weekly CDDP + RT has shown mild toxicity compared to tri-weekly CDDP + RT for LA-HNSCC and is a promising option for older adults. We aimed to report the treatment outcomes and prognostic factors in patients with LA-HNSCC treated with weekly CDDP + RT. METHODS: We analyzed patients aged ≥ 70 years who started weekly CDDP + RT for LA-HNSCC between July 2006 and October 2022. LA-HNSCC includes cancer in the oropharynx, hypopharynx, or larynx with a clinical stage of 3 or 4 without distant metastases based on the Union for International Cancer Control staging system 8th edition. The radiation dose of 70 Gy was delivered in 35 fractions by 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy. The primary endpoint was the 3-year overall survival (OS), and the secondary endpoints were the 3-year progression-free survival (PFS) and 3-year cause-specific survival (CSS). The Kaplan-Meier method was used to calculate survival rates, and the log-rank test was used to evaluate statistical significance. A Cox proportional hazards model was used for the multivariate analysis of prognostic factors. RESULTS: The median age of the 49 patients was 72 (range: 70-78) years. The median CDDP dose was 200 (40-280) mg/ m2, and 47 patients completed scheduled radiotherapy. Forty-eight patients (98.0%) had a performance status of ≥ 1 at the initial visit. The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8-90.7), 68.3% (95% CI 51.8-81.2), and 85.0% (95% CI 68.7-93.4), respectively. In the multivariate analysis, the cumulative CDDP dose (< 200 or ≥ 200 mg/m2) was a significant factor for OS (hazard ratio: 0.29 [95% CI 0.08-0.97], p = 0.044). There was one case of early mortality. Grade 3 or higher late adverse events were observed in four patients (8.2%). CONCLUSIONS: Weekly CDDP + RT in older patients led to good survival outcomes with an acceptable rate of adverse events. CDDP should be administered at a dose of at least 200 mg/m2 in older patients. Trial registration Retrospectively registered.

Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
Yasuhiro Dekura, Koichi Yasuda, Hideki Minatogawa, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takashi Mori, Kentaro Nishioka, Keiji Kobashi, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
Journal of radiation research, 2023年11月10日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.

Comparative study of physiological FDG uptake in small structures between silicon photomultiplier-based PET and conventional PET.
Shiro Watanabe, Kenji Hirata, Keiichi Magota, Junki Takenaka, Naoto Wakabayashi, Daiki Shinyama, Koichi Yasuda, Akihiro Homma, Kohsuke Kudo
Annals of nuclear medicine, 2023年11月09日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: Silicon photomultiplier-based positron emission tomography/computed tomography (SiPM-PET/CT) has the superior spatial resolution to conventional PET/CT (cPET/CT). This head-to-head comparison study compared the images of physiological 18F-fluorodeoxyglucose (FDG) accumulation in small-volume structures between SiPM-PET/CT and cPET/CT in patients scanned with both modalities, and we investigated whether the thresholds that are reported to be useful for differentiating physiological accumulations from malignant lesions can also be applied to SiPM-PET/CT. METHODS: We enrolled 21 consecutive patients with head and neck malignancies who underwent whole-body FDG-PET/CT for initial staging or a follow-up evaluation (October 2020 to March 2022). After being injected with FDG, all patients underwent PET acquisition on both Vereos PET-CT and Gemini TF64 PET-CT systems (both Philips Healthcare) in random order. For each patient, the maximum standardized uptake value (SUVmax) was measured in the pituitary gland, esophagogastric junction (EGJ), adrenal glands, lumbar enlargement of the spinal cord, and epididymis. We measured the liver SUVmean and the blood pool SUVmean to calculate the target-to-liver ratio (TLR) and the target-to-blood ratio (TBR), respectively. Between-groups differences in each variable were examined by a paired t-test. We also investigated whether there were cases of target uptake greater than the reported threshold for distinguishing pathological from physiological accumulations. RESULTS: Data were available for 19 patients. Ten patients were in Group 1, i.e., the patients who underwent SiPM-PET first, and the remaining nine patients who underwent cPET first were in Group 2. In the SiPM-PET results, the SUVmax of all targets was significantly higher than that obtained by cPET in all patients, and this tendency was also observed when the patients were divided into Groups 1/2. The TLRs of all targets were significantly higher in SiPM-PET than in cPET in all patients, and SiPM-PET also showed significantly higher TBRs for all targets except the EGJ (p = 0.052). CONCLUSIONS: The physiological uptake in the small structures studied herein showed high accumulation on SiPM-PET. Our results also suggest that the thresholds reported for cPET to distinguish pathological accumulations likely lead to false-positive findings in SIPM-PET evaluations.

Adjuvant treatments for locally advanced differentiated thyroid cancer: a nationwide survey in Japan.
Terufumi Kawamoto, Koichi Yasuda, Yoshinori Ito, Sadamoto Zenda, Katsuyuki Sakanaka, Naoto Shikama, Naoki Nakamura, Takashi Mizowaki
Endocrine journal, 2023年09月30日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, The role of adjuvant external-beam radiotherapy (EBRT) for locally advanced differentiated thyroid cancer (DTC) is controversial because of the lack of prospective data. To prepare for a clinical trial, this study investigated the current clinical practice of adjuvant treatments for locally advanced DTC. A survey on treatment selection criteria for hypothetical locally advanced DTC was administered to representative thyroid surgeons of facilities participating in the Japan Clinical Oncology Group Radiation Therapy Study Group. Of the 43 invited facilities, surgeons from 39 (91%) completed the survey. For R1 resection or suspected residual disease, 26 (67%) facilities administered high-dose (100-200 mCi) radioactive iodine (RAI), but none performed EBRT. For R2 resection or unresectable primary disease, 26 (67%) facilities administered high-dose RAI and 7 (18%) performed adjuvant treatments, including EBRT. For complete resection with nodal extra-capsular extension, 13 (34%) facilities administered high-dose RAI and 1 (3%) performed EBRT. For unresectable mediastinal lymph node metastasis, 31 (79%) facilities administered high-dose RAI and 5 (13%) performed adjuvant treatments, including EBRT. Adjuvant EBRT was not routinely performed mainly because of the lack of evidence for efficacy (74%). Approximately 15% of the facilities routinely considered adjuvant EBRT for DTC with R2 resection or unresectable primary or lymph node metastasis disease. Future clinical trials will need to optimize EBRT for these patients.

Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and the gastrointestinal tract using daily computed tomography images
Yusuke Uchinami, Takahiro Kanehira, Keiji Nakazato, Yoshihiro Fujita, Fuki Koizumi, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Kentaro Nishioka, Naoki Miyamoto, Kohei Yokokawa, Ryusuke Suzuki, Keiji Kobashi, Keita Takahashi, Norio Katoh, Hidefumi Aoyama
BJR|Open, 5, 1, British Institute of Radiology, 2023年08月, ［査読有り］
研究論文（学術雑誌）, Objectives:

We aimed to investigate whether daily computed tomography (CT) images could predict the daily gastroduodenal, small intestine, and large intestine doses of stereotactic body radiation therapy (SBRT) for pancreatic cancer based on the shortest distance between the gross tumor volume (GTV) and gastrointestinal (GI) tract.

Methods:

Twelve patients with pancreatic cancer received SBRT of 40 Gy in five fractions. We recalculated the reference clinical SBRT plan (PLAN_ref) using daily CT images and calculated the shortest distance from the GTV to each GI tract. The maximum dose delivered to 0.5 cc (D_0.5cc) was evaluated for each planning at-risk volume of the GI tract. Spearman’s correlation test was used to determine the association between the daily change in the shortest distance (Δshortest distance) and the ratio of ΔD_0.5cc dose to D_0.5cc dose in PLAN_ref (ΔD_0.5cc/PLAN_ref) for quantitative analysis.

Results:

The median shortest distance in PLAN_ref was 0 mm in the gastroduodenum (interquartile range, 0–2.7), 16.7 mm in the small intestine (10.0–23.7), and 16.7 mm in the large intestine (8.3–28.1 mm). The D_0.5cc of PLAN_ref in the gastroduodenum was >30 Gy in all patients, with 10 (83.3%) having the highest dose. A significant association was found between the Δshortest distance and ΔD_0.5cc/ PLAN_ref in the small or large intestine (p < 0.001) but not in the gastroduodenum (p = 0.404).

Conclusions:

The gastroduodenum had a higher D_0.5cc and predicting the daily dose was difficult. Daily dose calculations of the GI tract are recommended for safe SBRT.

Advances in knowledge:

This study aimed to predict the daily doses in SBRT for pancreatic cancer from the shortest distance between the GTV and the gastrointestinal tract. Daily changes in the shortest distance can predict the daily dose to the small or large intestines, but not to the gastroduodenum.

Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer.
Akihiro Homma, Mizuo Ando, Nobuhiro Hanai, Hiroyuki Harada, Yoshitaka Honma, Tomonori Kanda, Satoshi Kano, Daisuke Kawakita, Naomi Kiyota, Yoshiyuki Kizawa, Masahiro Nakagawa, Takenori Ogawa, Hirotaka Shinomiya, Takeshi Shinozaki, Motoyuki Suzuki, Tetsuya Tsuji, Koichi Yasuda, Sadamoto Zenda, Takeshi Kodaira, Tadaaki Kirita, Ken-Ichi Nibu
Auris, nasus, larynx, 2023年07月21日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The aim of the "Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2022 Update" is to review the latest evidence regarding head and neck cancer and to present the current standard approaches for diagnosis and treatment. These evidence-based recommendations were created with the consensus of the Guideline Committee, which is composed of otorhinolaryngologists and head and neck surgeons, together with radiologists, radiation oncologists, medical oncologists, plastic surgeons, dentists, palliative care physicians, and rehabilitation physicians. These guidelines were created by the Clinical Practice Guideline Committee of the Japan Society for Head and Neck Cancer based on the "Head and Neck Cancer Treatment Guidelines 2018 Edition," and the revised draft was compiled after evaluation by the Assessment Committee and public comments. The 'Clinical questions and recommendations' section consists of 13 categories, and 59 clinical questions are described in total. Here we describe 6 clinical questions specific to other sets of guidelines with recommendations and comments.

Treatment outcomes of the patient with sinonasal mucosal melanoma: the role of endoscopic resection and postoperative radiotherapy.
Nayuta Tsushima, Satoshi Kano, Koichi Yasuda, Takayoshi Suzuki, Seijiro Hamada, Yuji Nakamaru, Masanobu Suzuki, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
International journal of clinical oncology, 28, 9, 1218, 1226, 2023年06月17日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The standard of care for sinonasal mucosal melanoma is surgery and postoperative radiotherapy (PORT). Our treatment strategy comprises endoscopic resection and PORT. We performed combined endoscopic and open resection or applied an external approach alone when sufficient resection was difficult to achieve endoscopically. The objective of this study was to evaluate the validity of our treatment strategy. METHODS: We assessed 30 patients with sinonasal mucosal melanoma who underwent definitive therapy between January 2002 and April 2021, and conducted a retrospective analysis. The median follow-up period was 2.2 years. The primary endpoint was overall survival. The Kaplan-Meier method was used for the calculation of survival rates, the cumulative incidence of distant metastasis, and local recurrence. RESULTS: Twenty-eight patients underwent surgery. The other two patients were treated by definitive proton beam therapy. Twenty-one of 28 (75%) patients underwent resection by endoscopic approach alone. Postoperative radiotherapy was performed for all 28 patients who underwent surgery. Twenty-one patients (70%) experienced recurrence during the observation period. Overall, distant metastasis was observed in 19 patients. Twelve patients died during the observation period, with 10 of the 12 patients (83%) dying of distant metastasis. The overall survival rate at 2 and 5 years was 70% and 46%, respectively. The cumulative incidence rate of distant metastasis at 2 years was 63%, while the 2-year cumulative incidence rate of local recurrence was 6.7%. CONCLUSION: The local disease was controlled by our treatment strategy. To improve treatment outcomes, control of the distant metastasis is needed.

The superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is effective for metastatic lymph nodes in head and neck squamous cell carcinoma.
Satoshi Kano, Takayoshi Suzuki, Daisuke Yoshida, Nayuta Tsushima, Seijiro Hamada, Koichi Yasuda, Yusuke Uchinami, Hidefumi Aoyama, Akihiro Homma
International journal of clinical oncology, 28, 9, 1121, 1128, 2023年06月08日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) is a very promising treatment modality for locally advanced head and neck squamous cell carcinoma. However, there are some concerns regarding its potential for the control of neck lymph node metastasis. The objective of this study was to investigate whether RADPLAT provided inferior regional control compared to intravenous chemoradiotherapy (IV-CRT). METHODS: A total of 172 patients with neck lymph node metastases, 66 of whom underwent RADPLAT and 106 IV-CRT, were enrolled in this study. We retrospectively compared regional control rates between RADPLAT and IV-CRT. Furthermore, to adjust for differences in factors related to patient background between the groups, we conducted inverse probability weighting (IPW) analysis using the propensity score. RESULTS: A comparison between the two groups revealed that the regional control rates were almost equal under unadjusted conditions; however, after adjustment by IPW analysis, the RADPLAT group had a relatively better regional control rate than did the IV-CRT group (1 year regional control rate: 86.6% vs. 79.4%). In addition, the analysis of relative risk factors for regional control in the RADPLAT group showed that the absence of intra-arterial cisplatin infusion into metastatic lymph nodes was the only independent risk factor (Hazard ratio: 4.23, p = 0.04). CONCLUSION: This study showed that the regional control rate in patients treated with RADPLAT was noninferior to that for IV-CRT. Locally advanced head and neck cancers is a good indication for RADPLAT, even if the patients have neck lymph node metastases.

Proton beam therapy for gliomas: a multicenter prospective registry study from all proton beam facilities in Japan
Takashi Mori, Masashi Mizumoto, Katsuya Maebayashi, Kentaro Nishioka, Yoshiki Arakawa, Kazuhiko Kurozumi, Koichi Yasuda, Taisuke Sumiya, Hiroyasu Tamamura, Yoshitaka Sato, Takahiro Waki, Masaru Takagi, Yu Takada, Tomoaki Okimoto, Masao Murakami, Yasuhiro Kikuchi, Kazufumi Okada, Yoichi M Ito, Tetsuo Akimoto, Hidefumi Aoyama
Journal of Radiation Research, Oxford University Press (OUP), 2023年04月07日, ［査読有り］
研究論文（学術雑誌）, Abstract

We reviewed the outcomes of glioma patients enrolled in a prospective observational registry study of proton beam therapy (PBT) in Japan. The inclusion criteria were glioma patients registered in the Electronic Data Capture system, the Proton-net, between May 2016 and July 2019. Data on patient characteristics, treatments, late adverse events, survival status, recurrence and secondary tumors were extracted and statistically analyzed. The primary endpoint was the overall survival (OS) rate, and the secondary endpoints were the progression-free survival (PFS) rate and cumulative local recurrence rate (cLRR). Of the 65 primary brain tumor patients registered, 29 glioma patients from eight of 19 PBT facilities met the inclusion criteria. There were 19 glioblastoma patients, eight of other malignant gliomas, and two of low-grade gliomas. For glioblastomas, with a median follow-up period of 16 months, the median survival time was 21.2 months and the OS at 1, 2, 3 and 4 years were 77.4%, 44.9%, 23.9% and 23.9%, respectively. The median PFS period was 10.1 months, the 1, 2, 3 and 4-year PFS were 32.4%, 19.4%, 9.7% and 9.7%, respectively. The 1, 2, 3 and 4-year cLRR were 56.1%, 68.8%, 78.4 and 78.4%, respectively. Grade 3 brain necrosis was observed in two patients. No secondary tumor was observed. This is the first report on the current status of PBT for gliomas in Japan. For glioblastomas, the outcomes of PBT are estimated to be equivalent to historical data of photon therapy. The results of a prospective comparative evaluation of PBT and photon therapy are awaited.

Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer
Yusuke Uchinami, Takahiro Kanehira, Yoshihiro Fujita, Naoki Miyamoto, Kohei Yokokawa, Fuki Koizumi, Motoyasu Shido, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Keiji Nakazato, Keiji Kobashi, Norio Katoh, Hidefumi Aoyama
Clinical and Translational Radiation Oncology, 39, 100576, 100576, Elsevier BV, 2023年03月, ［査読有り］
研究論文（学術雑誌）

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Hajime Higaki, Kentaro Nishioka, Manami Otsuka, Noboru Nishikawa, Motoyasu Shido, Hideki Minatogawa, Yukiko Nishikawa, Rikiya Takashina, Takayuki Hashimoto, Norio Katoh, Hiroshi Taguchi, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Yusuke Uchinami, Fuki Koizumi, Yoshihiro Fujita, Shuhei Takahashi, Takahiro Hattori, Noriaki Nishiyama, Hidefumi Aoyama
Radiation oncology (London, England), 18, 1, 25, 25, 2023年02月07日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.

Deformed dose restoration to account for tumor deformation and position changes for adaptive proton therapy.
Koichi Miyazaki, Yusuke Fujii, Takahiro Yamada, Takahiro Kanehira, Naoki Miyamoto, Taeko Matsuura, Koichi Yasuda, Yusuke Uchinami, Manami Otsuka, Hidefumi Aoyama, Seishin Takao
Medical physics, 50, 2, 675, 687, 2022年12月11日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Online adaptation during intensity-modulated proton therapy (IMPT) can minimize the effect of inter-fractional anatomical changes, but remains challenging because of the complex workflow. One approach for fast and automated online IMPT adaptation is dose restoration, which restores the initial dose distribution on the updated anatomy. However, this method may fail in cases where tumor deformation or position changes occur. PURPOSE: To develop a fast and robust IMPT online adaptation method named "deformed dose restoration (DDR)" that can adjust for inter-fractional tumor deformation and position changes. METHODS: THE DDR METHOD COMPRISES TWO STEPS: : (1) calculation of the deformed dose distribution, and (2) restoration of the deformed dose distribution. First, the deformable image registration (DIR) between the initial clinical target volume (CTV) and the new CTV were performed to calculate the vector field. To ensure robustness for setup and range uncertainty and the ability to restore the deformed dose distribution, an expanded CTV-based registration to maintain the dose gradient outside the CTV was developed. The deformed dose distribution was obtained by applying the vector field to the initial dose distribution. Then, the voxel-by-voxel dose difference optimization was performed to calculate beam parameters that restore the deformed dose distribution on the updated anatomy. The optimization function was the sum of total dose differences and dose differences of each field to restore the initial dose overlap of each field. This method only requires target contouring, which eliminates the need for organs at risk (OARs) contouring. Six clinical cases wherein the tumor deformation and/or position changed on repeated CTs were selected. DDR feasibility was evaluated by comparing the results with those from three other strategies, namely, not adapted (continuing the initial plan), adapted by previous dose restoration, and fully optimized. RESULTS: In all cases, continuing the initial plan was largely distorted on the repeated CTs and the dose-volume histogram (DVH) metrics for the target were reduced due to the tumor deformation or position changes. On the other hand, DDR improved DVH metrics for the target to the same level as the initial dose distribution. Dose increase was seen for some OARs because tumor growth had reduced the relative distance between CTVs and OARs. Robustness evaluation for setup and range uncertainty (3 mm/3.5%) showed that deviation in DVH-bandwidth for CTV D95% from the initial plan was 0.4 ± 0.5% (Mean ± S.D.) for DDR. The calculation time was 8.1 ± 6.4 min. CONCLUSIONS: An online adaptation algorithm was developed that improved the treatment quality for inter-fractional anatomical changes and retained robustness for intra-fractional setup and range uncertainty. The main advantage of this method is that it only requires target contouring alone and saves the time for OARs contouring. The fast and robust adaptation method for tumor deformation and position changes described here can reduce the need for offline adaptation and improve treatment efficiency. This article is protected by copyright. All rights reserved.

Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy.
Manami Otsuka, Koichi Yasuda, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Ryusuke Suzuki, Naoki Miyamoto, Hideki Minatogawa, Yasuhiro Dekura, Takashi Mori, Kentaro Nishioka, Jun Taguchi, Yasushi Shimizu, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
Journal of medical imaging and radiation oncology, 67, 1, 98, 110, 2022年11月14日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, INTRODUCTION: Sequential boost intensity-modulated radiotherapy (SQB-IMRT) uses two different planning CTs (pCTs) and treatment plans. SQB-IMRT is a form of adaptive radiotherapy that allows for responses to changes in the shape of the tumour and organs at risk (OAR). On the other hand, dose accumulation with the two plans can be difficult to evaluate. The purpose of this study was to analyse patterns of loco-regional failure using deformable image registration (DIR) in hypopharyngeal cancer patients treated with SQB-IMRT. METHODS: Between 2013 and 2019, 102 patients with hypopharyngeal cancer were treated with definitive SQB-IMRT at our institution. Dose accumulation with the 1st and 2nd plans was performed, and the dose to the loco-regional recurrent tumour volume was calculated using the DIR workflow. Failure was classified as follows: (i) in-field (≥95% of the recurrent tumour volume received 95% of the prescribed dose); (ii) marginal (20-95%); or (iii) out-of-field (<20%). RESULTS: After a median follow-up period of 25 months, loco-regional failure occurred in 34 patients. Dose-volume histogram analysis showed that all loco-regional failures occurred in the field within 95% of the prescribed dose, with no marginal or out-of-field recurrences observed. CONCLUSION: The dosimetric analysis using DIR showed that all loco-regional failures were within the high-dose region. More aggressive treatment may be required for gross tumours.

Hyperfractionated intensity-modulated proton therapy for pharyngeal cancer with variable relative biological effectiveness: A simulation study.
Koki Kasamatsu, Taeko Matsuura, Koichi Yasuda, Koichi Miyazaki, Seishin Takao, Masaya Tamura, Manami Otsuka, Yusuke Uchinami, Hidefumi Aoyama
Medical physics, 49, 12, 7815, 7825, 2022年10月27日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The relative biological effectiveness (RBE) of proton is considered to be dependent on biological parameters and fractional dose. While hyperfractionated photon therapy was effective in the treatment of patients with head and neck cancers, its effect in intensity-modulated proton therapy (IMPT) under the variable RBE has not been investigated in detail. PURPOSE: To study the effect of variable RBE on hyperfractionated IMPT for the treatment of pharyngeal cancer. We investigated the biologically effective dose (BED) to determine the theoretical effective hyperfractionated schedule. METHODS: The treatment plans of three pharyngeal cancer patients were used to define the ΔBED for the clinical target volume (CTV) and soft tissue (acute and late reaction) as the difference between the BED for the altered schedule with variable RBE and conventional schedule with constant RBE. The ΔBED with several combinations of parameters (treatment days, number of fractions, and prescribed dose) was comprehensively calculated. Of the candidate schedules, the one that commonly gave a higher ΔBED for CTV was selected as the resultant schedule. The BED volume histogram was used to compare the influence of variable RBE and fractionation. RESULTS: In the conventional schedule, compared with the constant RBE, the variable RBE resulted in a mean 2.6 and 2.7 Gy reduction of BEDmean for the CTV and soft tissue (acute reaction) of the three plans, respectively. Moreover, the BEDmean for soft tissue (late reaction) increased by 7.4 Gy, indicating a potential risk of increased RBE. Comprehensive calculation of the ΔBED resulted in the hyperfractionated schedule of 80.52 Gy (RBE = 1.1)/66 fractions in 6.5 weeks. When variable RBE was used, compared with the conventional schedule, the hyperfractionated schedule increased the BEDmean for CTV by 7.6 Gy; however, this was associated with a 7.8 Gy increase for soft tissue (acute reaction). The BEDmean for soft tissue (late reaction) decreased by 2.4 Gy. CONCLUSION: The results indicated a potential effect of the variable RBE on IMPT for pharyngeal cancer but with the possibility that hyperfractionation could outweigh this effect. Although biological uncertainties require conservative use of the resultant schedule, hyperfractionation is expected to be an effective strategy in IMPT for pharyngeal cancer.

A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity.
Yusuke Uchinami, Norio Katoh, Ryusuke Suzuki, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Naoki Miyamoto, Yoshihiro Fujita, Fuki Koizumi, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Clinical and translational radiation oncology, 35, 70, 75, 2022年07月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Background: For small primary liver tumors, favorable outcomes have been reported with both of proton beam therapy (PBT) and X-ray therapy (XRT). However, no clear criteria have been proposed in the cases for which and when of PBT or XRT has to be used. The aim of this study is to investigate cases that would benefit from PBT based on the predicted rate of hepatic toxicity. Materials and methods: Eligible patients were those who underwent PBT for primary liver tumors with a maximum diameter of ≤ 5 cm and Child-Pugh grade A (n = 40). To compare the PBT-plan, the treatment plan using volumetric modulated arc therapy was generated as the XRT-plan. The rate of predicted hepatic toxicity was estimated using five normal tissue complication probability (NTCP) models with three different endpoints. The differences in NTCP values (ΔNTCP) were calculated to determine the relative advantage of PBT. Factors predicting benefits of PBT were analyzed by logistic regression analysis. Results: From the dose-volume histogram comparisons, an advantage of PBT was found in sparing of the normal liver receiving low doses. The factors predicting the benefit of PBT differed depending on the selected NTCP model. From the five models, the total tumor diameter (sum of the target tumors), location (hepatic hilum vs other), and number of tumors (1 vs 2) were significant factors. Conclusions: From the radiation-related hepatic toxicity, factors were identified to predict benefits of PBT in primary liver tumors with Child-Pugh grade A, with the maximum tumor diameter of ≤ 5 cm.

Systemic therapy for salivary gland malignancy: current status and future perspectives.
Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Tomoya Yokota, Susumu Okano, Kaoru Tanaka, Takuma Onoe, Yosuke Ariizumi, Akihiro Homma
Japanese journal of clinical oncology, 52, 4, 293, 302, 2022年04月06日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Salivary gland malignancies are rare neoplasms that have a broad histological spectrum and a variety of biologic behaviors. Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. This review summarizes the role of systemic therapy for salivary gland malignancies. To date, the advantage of adding concurrent chemotherapy has remained undefined for both postoperative and inoperable locally advanced salivary gland malignancy patients undergoing radiotherapy. For recurrent/metastatic disease, local and/or systemic treatment options should be discussed in a multidisciplinary setting with consideration to both patient needs and tumor factors. For symptomatic patients or those who may compromise organ function, palliative systemic therapy can be a reasonable option based on the results of phase II studies. Platinum combination regimens as first-line therapy have been widely accepted. Personalized therapies have become established options, particularly for androgen receptor-positive, HER2-positive and NTRK fusion-positive salivary gland malignancies (i.e. androgen receptor and HER2 in salivary duct carcinoma and NTRK3 in secretory carcinoma). For patients with adenoid cystic carcinoma, multi-targeted tyrosine kinase inhibitors have also been developed. Anti-PD1 checkpoint inhibitors have shown limited activity to date. Investigation of active systemic treatments for salivary gland malignancy remains a significant unmet need. Future directions might include a more comprehensive genomic screening approach (usually next-generation sequencing-based) and combination strategies using immune checkpoint inhibitors. These are rare malignancies that require ongoing effort in the conduct of high-quality clinical trials.

Human papillomavirus-related oropharyngeal carcinoma.
Yuki Saito, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Tomoya Yokota, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
Japanese journal of clinical oncology, 52, 7, 692, 698, 2022年04月05日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.

Management of elderly patients with head and neck cancer.
Ryo Ishii, Akira Ohkoshi, Naomi Kiyota, Kazuto Matsuura, Koichi Yasuda, Yoshinori Imamura, Yuki Saito, Akihiro Homma
Japanese journal of clinical oncology, 52, 4, 313, 321, 2022年02月15日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, There are no established guidelines for managing older patients with head and neck cancer. Most clinical trials that define current standard therapy included few elderly patients. On the other hand, there is great variability in patients' comorbidities, physical functions, cognitive function, familial and financial background and values. The key point appears to be appropriate geriatric assessment, clarifying the patients' outcomes and a multidisciplinary team approach, including the treatment decision-making policy. Although these processes should be scientific in nature, the evidence for the treatment of elderly head and neck patients is very limited. This review summarizes the evidence available regarding the management of geriatric assessment, each treatment modality and the multidisciplinary team approach for older patients with head and neck cancers.

Prediction of the local treatment outcome in patients with oropharyngeal squamous cell carcinoma using deep learning analysis of pretreatment FDG-PET images.
Noriyuki Fujima, V Carlota Andreu-Arasa, Sara K Meibom, Gustavo A Mercier, Minh Tam Truong, Kenji Hirata, Koichi Yasuda, Satoshi Kano, Akihiro Homma, Kohsuke Kudo, Osamu Sakai
BMC cancer, 21, 1, 900, 900, 2021年08月06日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: This study aimed to assess the utility of deep learning analysis using pretreatment FDG-PET images to predict local treatment outcome in oropharyngeal squamous cell carcinoma (OPSCC) patients. METHODS: One hundred fifty-four OPSCC patients who received pretreatment FDG-PET were included and divided into training (n = 102) and test (n = 52) sets. The diagnosis of local failure and local progression-free survival (PFS) rates were obtained from patient medical records. In deep learning analyses, axial and coronal images were assessed by three different architectures (AlexNet, GoogLeNET, and ResNet). In the training set, FDG-PET images were analyzed after the data augmentation process for the diagnostic model creation. A multivariate clinical model was also created using a binomial logistic regression model from a patient's clinical characteristics. The test data set was subsequently analyzed for confirmation of diagnostic accuracy. Assessment of local PFS rates was also performed. RESULTS: Training sessions were successfully performed with an accuracy of 74-89%. ROC curve analyses revealed an AUC of 0.61-0.85 by the deep learning model in the test set, whereas it was 0.62 by T-stage, 0.59 by clinical stage, and 0.74 by a multivariate clinical model. The highest AUC (0.85) was obtained with deep learning analysis of ResNet architecture. Cox proportional hazards regression analysis revealed deep learning-based classification by a multivariate clinical model (P < .05), and ResNet (P < .001) was a significant predictor of the treatment outcome. In the Kaplan-Meier analysis, the deep learning-based classification divided the patient's local PFS rate better than the T-stage, clinical stage, and a multivariate clinical model. CONCLUSIONS: Deep learning-based diagnostic model with FDG-PET images indicated its possibility to predict local treatment outcomes in OPSCCs.

Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas.
Yusuke Uchinami, Norio Katoh, Daisuke Abo, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Takeshi Soyama, Ryo Morita, Naoki Miyamoto, Ryusuke Suzuki, Takuya Sho, Masato Nakai, Koji Ogawa, Tatsuhiko Kakisaka, Tatsuya Orimo, Toshiya Kamiyama, Shinichi Shimizu, Hidefumi Aoyama
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 870, 879, 2021年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, AIM: To report the outcomes of stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinoma patients. METHODS: From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. No patient with a Child-Pugh Score ≥9 was included, and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with an α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range 60-122.5 Gy). Overall survival (OS) and local control rates were assessed using the Kaplan-Meier method. RESULTS: With a median follow-up period of 24.6 months (range 0.9-118.4 months), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI] 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1, and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs. ≥2a) was a significant factor for OS (p = 0.028, 95% CI 1.11-6.18). The 1-year and 2-year local control rates were 100% (100-100%) and 92.0% (77.5-97.5%). The local control rates were significantly higher in the BED10 ≥100 Gy group than in the BED10 <100 Gy group (2-year 100% vs. 86.5%, p = 0.049) at the reference point. CONCLUSION: This retrospective study of stereotactic body radiotherapy using real-time tumor-tracking radiotherapy for hepatocellular carcinoma showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 ≥100 Gy to the reference point.

Predictors of the need for prophylactic percutaneous endoscopic gastrostomy in head and neck cancer patients treated with concurrent chemoradiotherapy.
Satoshi Kano, Nayuta Tsushima, Takayoshi Suzuki, Seijiro Hamada, Taizo Yokokawa, Hiroshi Idogawa, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Hidefumi Aoyama, Akihiro Homma
International journal of clinical oncology, 26, 7, 1179, 1187, 2021年07月, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: We investigated whether prophylactic percutaneous endoscopic gastrostomy (PEG) is used effectively for patients treated with definitive concurrent chemoradiotherapy (CCRT) and the predictors of the need for PEG. METHODS: 326 patients with laryngeal, oropharyngeal or hypopharyngeal cancers were retrospectively reviewed. RESULTS: The PEG tube use group had more favorable results than the total parenteral nutrition and nasogastric tube groups in terms of rate of serum albumin loss, incidence of severe fever and aspiration pneumonia, CCRT completion rate and hospitalization period. However, it was inferior to oral intake. Analysis of the relative risk of requiring enteral or parenteral nutrition revealed that performance status (PS) 2, primary site (supraglottis, oropharynx, or hypopharynx), N3 disease, and cisplatin were predictors of the need for nutritional support. CONCLUSIONS: Prophylactic PEG is effective for patients treated with definitive CCRT and is especially required for patients with PS2 or oropharyngeal cancer.

Salvage surgery improves the treatment outcome of patients with residual/recurrent maxillary sinus cancer after superselective intra-arterial cisplatin infusion with concomitant radiation therapy.
Nayuta Tsushima, Satoshi Kano, Takayoshi Suzuki, Hiroshi Idogawa, Daisuke Yoshida, Koichi Yasuda, Manami Otsuka, Hidefumi Aoyama, Akihiro Homma
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279, 2, 899, 905, 2021年04月18日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: We have performed superselective intra-arterial cisplatin infusion with concomitant radiotherapy (RADPLAT) for patients with maxillary sinus cancer. The promising treatment outcomes of this non-surgical treatment were reported in past studies. However, few clinical studies have been conducted to evaluate the outcome of salvage surgery following RADPLAT. The purpose of this study was to analyze the treatment outcomes of salvage surgery for patients with recurrent maxillary sinus cancer after RADPLAT. METHODS: We assessed 45 patients who had recurrence following RADPLAT between 1999 and 2017, and conducted a retrospective analysis. We excluded patients who did not complete RADPLAT. Patients were not considered to have completed RADPLAT if they underwent intra-arterial cisplatin less than three times or received a total radiation dose of less than 60 Gy. The primary endpoint was overall survival. The median follow-up period for surviving patients after recurrence was 5.1 years. RESULTS: Twenty-five of the 45 (56%) patients underwent salvage surgery. The 5-year overall survival rate was 68% in patients who underwent salvage surgery, while all patients who did not undergo salvage surgery died during the observation period. Fifteen of 24 (63%) patients with local recurrence underwent salvage surgery. Eight patients did not undergo salvage surgery because of unresectable disease; five of the eight patients had unresectable posterior extension. All nine patients with nodal recurrence underwent neck dissection. CONCLUSION: Treatment outcomes of salvage surgery following RADPLAT were favorable enough for it to be generally recommended. To reduce unresectable recurrence, the posterior section should be eradicated by RADPLAT.

Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Seishin Takao, Masaya Tamura, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takatsugu Mizumachi, Takashi Mori, Kentaro Nishioka, Motoyasu Shido, Norio Katoh, Hiroshi Taguchi, Noriyuki Fujima, Rikiya Onimaru, Isao Yokota, Keiji Kobashi, Shinichi Shimizu, Akihiro Homma, Hiroki Shirato, Hidefumi Aoyama
Journal of radiation research, 62, 2, 329, 337, 2021年03月10日, ［査読有り］, ［筆頭著者, 責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Susumu Okano, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Tomoya Yokota, Yoshinori Imamura, Yosuke Ariizumi, Tetsuo Akimoto, Ryuichi Hayashi
Japanese journal of clinical oncology, 51, 2, 173, 179, 2021年02月08日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.

The role of endoscopic resection for selected patients with sinonasal squamous cell carcinoma.
Yuji Nakamaru, Masanobu Suzuki, Satoshi Kano, Takatsugu Mizumachi, Nayuta Tsushima, Takayoshi Suzuki, Aya Honma, Akira Nakazono, Shogo Kimura, Rikiya Onimaru, Koichi Yasuda, Hiroki Shirato, Akihiro Homma
Auris, nasus, larynx, 48, 1, 131, 137, 2021年02月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: Despite of rapid advances in endoscopic surgery, the gold standard for sinonasal squamous cell carcinoma (SNSCC) surgery has remained the open approach with en-block resection due to the aggressive nature of SNSCC, including frequent recurrence and high mortality rate. For that reason, few studies have focused on SNSCC treated by endoscopic surgery alone. The objective of this study was to evaluate the usefulness of endoscopic surgery for patients with SNSCC. METHODS: A retrospective analysis was performed for 15 consecutive SNSCC patients who underwent endoscopic surgery without an open approach. We carefully selected patients whose tumor attachment sites could be fully visualized and completely resected through an endonasal approach. RESULTS: Of the fifteen patients, 4 patients (27%) were diagnosed with T1, 7 (47%) with T2, 4 (27%) with T3, and no patients with T4a or T4b disease. Four of the 15 (27%) patients showed positive surgical margins. The 5-yr overall survival, disease-specific survival, and local control rate was 72.4%, 79.6%, and 92.9%, respectively. The 5-yr disease-specific survival for T1, T2, and T3 disease was 100% and 75% and 75%, respectively. Patients with negative surgical margins had a better disease-specific survival rate than did those with positive surgical margins (p = 0.0253). CONCLUSION: Endoscopic surgery for patients with SNSCC appears to afford an effective method in selected cases. The achievement of negative surgical margins with a good view of the tumor attachment site was considered to be critical to the management of SNSCC.

Multiparametric Analysis of Tumor Morphological and Functional MR Parameters Potentially Predicts Local Failure in Pharynx Squamous Cell Carcinoma Patients.
Noriyuki Fujima, Yukie Shimizu, Daisuke Yoshida, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Koichi Yasuda, Rikiya Onimaru, Osamu Sakai, Kohsuke Kudo, Hiroki Shirato
The journal of medical investigation : JMI, 68, 3.4, 354, 361, 2021年, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, Purpose : To predict local control / failure by a multiparametric approach using magnetic resonance (MR)-derived tumor morphological and functional parameters in pharynx squamous cell carcinoma (SCC) patients. Materials and Methods : Twenty-eight patients with oropharyngeal and hypopharyngeal SCCs were included in this study. Quantitative morphological parameters and intratumoral characteristics on T2-weighted images, tumor blood flow from pseudo-continuous arterial spin labeling, and tumor diffusion parameters of three diffusion models from multi-b-value diffusion-weighted imaging as well as patients' characteristics were analyzed. The patients were divided into local control / failure groups. Univariate and multiparametric analysis were performed for the patient group division. Results : The value of morphological parameter of 'sphericity' and intratumoral characteristic of 'homogeneity' was revealed respectively significant for the prediction of the local control status in univariate analysis. Higher diagnostic performance was obtained with the sensitivity of 0.8, specificity of 0.75, positive predictive value of 0.89, negative predictive value of 0.6 and accuracy of 0.79 by multiparametric diagnostic model compared to results in the univariate analysis. Conclusion : A multiparametric analysis with MR-derived quantitative parameters may be useful to predict local control in pharynx SCC patients. J. Med. Invest. 68 : 354-361, August, 2021.

Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?
Kentaro Nishioka, Kento Gotoh, Takayuki Hashimoto, Takashige Abe, Takahiro Osawa, Ryuji Matsumoto, Isao Yokota, Norio Katoh, Rumiko Kinoshita, Koichi Yasuda, Toshiaki Yakabe, Takaaki Yoshimura, Seishin Takao, Nobuo Shinohara, Hidefumi Aoyama, Shinichi Shimizu, Hiroki Shirato
BJR|Open, 3, 1, 20210064, 20210064, British Institute of Radiology, 2021年01月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The purpose of this study is to investigate whether verbal instructions are sufficient for bladder volume (BV) control not to deteriorate prostate position reproducibility in image-guided spot scanning proton therapy (SSPT) for localized prostate cancer.

A total of 268 treatment sessions in 12 consecutive prostate cancer patients who were treated with image-guided SSPT with fiducial markers were retrospectively analyzed. In addition to strict rectal volume control procedures, simple verbal instructions to void urine one hour before the treatment were used here. The BV was measured by a Bladder Scan just before the treatment, and the prostate motion was measured by intraprostatic fiducial markers and two sets of X-ray fluoroscopy images. The correlation between the BV change and prostate motion was assessed by linear mixed-effects models and systematic and random errors according to the reproducibility of the BV.

The mean absolute BV change during treatment was from −98.7 to 86.3 ml (median 7.1 ml). The mean absolute prostate motion of the patients in the left-right direction was −1.46 to 1.85 mm; in the cranial-caudal direction it was −6.10 to 3.65 mm, and in the anteroposterior direction −1.90 to 5.23 mm. There was no significant relationship between the BV change and prostate motion during SSPT. The early and late genitourinary and gastrointestinal toxicity was minimal with a minimum follow up of 4.57 years.

Simple verbal instructions about urination was suggested to be sufficient to control the BV not to impact on the prostate motion and clinical outcomes in image-guided SSPT. Careful attention to BV change is still needed when the seminal vesicle is to be treated.

Our data demonstrated that there was no apparent relationship between BV changes and prostate position reproducibility and simple verbal instruction about urination could be sufficient for image-guided SSPT.

Potential benefits of adaptive intensity-modulated proton therapy in nasopharyngeal carcinomas.
Hideki Minatogawa, Koichi Yasuda, Yasuhiro Dekura, Seishin Takao, Taeko Matsuura, Takaaki Yoshimura, Ryusuke Suzuki, Isao Yokota, Noriyuki Fujima, Rikiya Onimaru, Shinichi Shimizu, Hidefumi Aoyama, Hiroki Shirato
Journal of applied clinical medical physics, 22, 1, 174, 183, 2021年01月, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To investigate potential advantages of adaptive intensity-modulated proton beam therapy (A-IMPT) by comparing it to adaptive intensity-modulated X-ray therapy (A-IMXT) for nasopharyngeal carcinomas (NPC). METHODS: Ten patients with NPC treated with A-IMXT (step and shoot approach) and concomitant chemotherapy between 2014 and 2016 were selected. In the actual treatment, 46 Gy in 23 fractions (46Gy/23Fx.) was prescribed using the initial plan and 24Gy/12Fx was prescribed using an adapted plan thereafter. New treatment planning of A-IMPT was made for the same patients using equivalent dose fractionation schedule and dose constraints. The dose volume statistics based on deformable images and dose accumulation was used in the comparison of A-IMXT with A-IMPT. RESULTS: The means of the Dmean of the right parotid gland (P < 0.001), right TM joint (P < 0.001), left TM joint (P < 0.001), oral cavity (P < 0.001), supraglottic larynx (P = 0.001), glottic larynx (P < 0.001), , middle PCM (P = 0.0371), interior PCM (P < 0.001), cricopharyngeal muscle (P = 0.03643), and thyroid gland (P = 0.00216), in A-IMPT are lower than those of A-IMXT, with statistical significance. The means of, D0.03cc , and Dmean of each sub portion of auditory apparatus and D30% for Eustachian tube and D0.5cc for mastoid volume in A-IMPT are significantly lower than those of A-IMXT. The mean doses to the oral cavity, supraglottic larynx, and glottic larynx were all reduced by more than 20 Gy (RBE = 1.1). CONCLUSIONS: An adaptive approach is suggested to enhance the potential benefit of IMPT compared to IMXT to reduce adverse effects for patients with NPC.

Construction of a detachable artificial trachea model for three age groups for use in an endotracheal suctioning training environment simulator.
Takaaki Yoshimura, Noriyo Colley, Shunsuke Komizunai, Shinji Ninomiya, Satoshi Kanai, Atsushi Konno, Koichi Yasuda, Hiroshi Taguchi, Takayuki Hashimoto, Shinichi Shimizu
PloS one, 16, 3, e0249010, 2021年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Tracheal suctioning is an important procedure to maintain airway patency by removing secretions. Today, suctioning operators include not only medical staff, but also family caregivers. The use of a simulation system has been noted to be the most effective way to learn the tracheal suctioning technique for operators. While the size of the trachea varies across different age groups, the artificial trachea model in the simulation system has only one fixed model. Thus, this study aimed to construct multiple removable trachea models according to different age groups. We enrolled 20 patients who had previously received proton beam therapy in our institution and acquired the treatment planning computed tomography (CT) image data. To construct the artificial trachea model for three age groups (children, adolescents and young adults, and adults), we analyzed the three-dimensional coordinates of the entire trachea, tracheal carina, and the end of the main bronchus. We also analyzed the diameter of the trachea and main bronchus. Finally, we evaluated the accuracy of the model by analyzing the difference between the constructed model and actual measurements. The trachea model was 8 cm long for children and 12 cm for adolescents and young adults, and for adults. The angle between the trachea and bed was about 20 degrees, regardless of age. The mean model accuracy was less than 0.4 cm. We constructed detachable artificial trachea models for three age groups for implementation in the endotracheal suctioning training environment simulator (ESTE-SIM) based on the treatment planning CT image. Our constructed artificial trachea models will be able to provide a simulation environment for various age groups in the ESTE-SIM.

Quantitative analysis of treatments using real-time image gated spot-scanning with synchrotron-based proton beam therapy system log data.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Sodai Tanaka, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 12, 10, 19, 2020年12月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, A synchrotron-based real-time image gated spot-scanning proton beam therapy (RGPT) system with inserted fiducial markers can irradiate a moving tumor with high accuracy. As gated treatments increase the beam delivery time, this study aimed to investigate the frequency of intra-field adjustments corresponding to the baseline shift or drift and the beam delivery efficiency of a synchrotron-based RGPT system. Data from 118 patients corresponding to 127 treatment plans and 2810 sessions between October 2016 and March 2019 were collected. We quantitatively analyzed the proton beam delivery time, the difference between the ideal beam delivery time based on a simulated synchrotron magnetic excitation pattern and the actual treatment beam delivery time, frequency corresponding to the baseline shift or drift, and the gating efficiency of the synchrotron-based RGPT system according to the proton beam delivery machine log data. The mean actual beam delivery time was 7.1 min, and the simulated beam delivery time in an ideal environment with the same treatment plan was 2.9 min. The average difference between the actual and simulated beam delivery time per session was 4.3 min. The average frequency of intra-field adjustments corresponding to baseline shift or drift and beam delivery efficiency were 21.7% and 61.8%, respectively. Based on our clinical experience with a synchrotron-based RGPT system, we determined the frequency corresponding to baseline shift or drift and the beam delivery efficiency using the beam delivery machine log data. To maintain treatment accuracy within ± 2.0 mm, intra-field adjustments corresponding to baseline shift or drift were required in approximately 20% of cases. Further improvements in beam delivery efficiency may be realized by shortening the beam delivery time.

Immunotherapy for squamous cell carcinoma of the head and neck.
Tomoya Yokota, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
Japanese journal of clinical oncology, 50, 10, 1089, 1096, 2020年09月28日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.

Difference in LET-based biological doses between IMPT optimization techniques: Robust and PTV-based optimizations.
Shusuke Hirayama, Taeko Matsuura, Koichi Yasuda, Seishin Takao, Takaaki Fujii, Naoki Miyamoto, Kikuo Umegaki, Shinichi Shimizu
Journal of applied clinical medical physics, 21, 4, 42, 50, 2020年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: While a large amount of experimental data suggest that the proton relative biological effectiveness (RBE) varies with both physical and biological parameters, current commercial treatment planning systems (TPS) use the constant RBE instead of variable RBE models, neglecting the dependence of RBE on the linear energy transfer (LET). To conduct as accurate a clinical evaluation as possible in this circumstance, it is desirable that the dosimetric parameters derived by TPS (

D

RBE
=
1.1


) are close to the "true" values derived with the variable RBE models (

D

v
RBE


). As such, in this study, the closeness of

D

RBE
=
1.1


to

D

v
RBE


was compared between planning target volume (PTV)-based and robust plans. METHODS: Intensity-modulated proton therapy (IMPT) treatment plans for two Radiation Therapy Oncology Group (RTOG) phantom cases and four nasopharyngeal cases were created using the PTV-based and robust optimizations, under the assumption of a constant RBE of 1.1. First, the physical dose and dose-averaged LET (LETd ) distributions were obtained using the analytical calculation method, based on the pencil beam algorithm. Next,

D

v
RBE


was calculated using three different RBE models. The deviation of

D

v
RBE


from

D

RBE
=
1.1


was evaluated with D99 and Dmax , which have been used as the evaluation indices for clinical target volume (CTV) and organs at risk (OARs), respectively. The influence of the distance between the OAR and CTV on the results was also investigated. As a measure of distance, the closest distance and the overlapped volume histogram were used for the RTOG phantom and nasopharyngeal cases, respectively. RESULTS: As for the OAR, the deviations of

D
max

v
RBE


from

D
max

RBE
=
1.1


were always smaller in robust plans than in PTV-based plans in all RBE models. The deviation would tend to increase as the OAR was located closer to the CTV in both optimization techniques. As for the CTV, the deviations of

D
99

v
RBE


from

D
99

RBE
=
1.1


were comparable between the two optimization techniques, regardless of the distance between the CTV and the OAR. CONCLUSION: Robust optimization was found to be more favorable than PTV-based optimization in that the results presented by TPS were closer to the "true" values and that the clinical evaluation based on TPS was more reliable.

Analysis of treatment process time for real-time-image gated-spot-scanning proton-beam therapy (RGPT) system.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Tetsuya Inoue, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 2, 38, 49, 2020年02月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, We developed a synchrotron-based real-time-image gated-spot-scanning proton-beam therapy (RGPT) system and utilized it to clinically operate on moving tumors in the liver, pancreas, lung, and prostate. When the spot-scanning technique is linked to gating, the beam delivery time with gating can increase, compared to that without gating. We aim to clarify whether the total treatment process can be performed within approximately 30 min (the general time per session in several proton therapy facilities), even for gated-spot-scanning proton-beam delivery with implanted fiducial markers. Data from 152 patients, corresponding to 201 treatment plans and 3577 sessions executed from October 2016 to June 2018, were included in this study. To estimate the treatment process time, we utilized data from proton beam delivery logs during the treatment for each patient. We retrieved data, such as the disease site, total target volume, field size at the isocenter, and the number of layers and spots for each field, from the treatment plans. We quantitatively analyzed the treatment process, which includes the patient load (or setup), bone matching, marker matching, beam delivery, patient unload, and equipment setup, using the data obtained from the log data. Among all the cases, 90 patients used the RGPT system (liver: n = 34; pancreas: n = 5; lung: n = 4; and prostate: n = 47). The mean and standard deviation (SD) of the total treatment process time for the RGPT system was 30.3 ± 7.4 min, while it was 25.9 ± 7.5 min for those without gating treatment, excluding craniospinal irradiation (CSI; head and neck: n = 16, pediatric: n = 31, others: n = 15); for CSI (n = 11) with two or three isocenters, the process time was 59.9 ± 13.9 min. Our results demonstrate that spot-scanning proton therapy with a gating function can be achieved in approximately 30-min time slots.

The Potential Benefit of Adaptive Intensity Modulated Proton Therapy in Nasopharyngeal Carcinoma: Planning Comparison Study
H. Minatogawa, K. Yasuda, T. Matsuura, R. Onimaru, T. Yoshimura, S. Takao, Y. Matsuo, Y. Dekura, R. Suzuki, M. Tamura, N. Miyamoto, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 105, 1, E394, E394, Elsevier BV, 2019年09月
研究論文（学術雑誌）

Impact of organ motion on volumetric and dosimetric parameters in stomach lymphomas treated with intensity-modulated radiotherapy.
Yusuke Uchinami, Ryusuke Suzuki, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Naoki Miyamoto, Yoichi M Ito, Shinichi Shimizu, Hiroki Shirato
Journal of applied clinical medical physics, 20, 8, 78, 86, 2019年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: Interplay effects may influence dose distributions to a moving target when using dynamic delivery techniques such as intensity-modulated radiotherapy (IMRT). The aim of this study was to evaluate the impact of organ motion on volumetric and dosimetric parameters in stomach lymphomas treated with IMRT. METHODS: Ten patients who had been treated with IMRT for stomach lymphomas were enrolled. The clinical target volume (CTV) was contoured as the whole stomach. Considering interfractional uncertainty, the internal target volume (ITV) margin was uniformly 1.5 cm to the CTV and then modified based on the 4DCT images in case of the large respiratory motion. The planning target volume (PTV) was created by adding 5 mm to the ITV. The impact of organ motion on the volumetric and dosimetric parameters was evaluated retrospectively (4D simulation). The organ motion was reproduced by shifting the isocenter on the radiation treatment planning system. Several simulation plans were created to test the influence of the beam-on timing in the respiration cycle on the dose distribution. The homogeneity index (HI), volume percentage of stomach covered by the prescribed dose (Vp ), and D99 of the CTV were evaluated. RESULTS: The organ motion was the largest in the superior-inferior direction (10.1 ± 4.5 mm [average ± SD]). Stomach volume in each respiratory phase compared to the mean volume varied approximately within a ± 5% range in most of the patients. The PTV margin was sufficiently large to cover the CTV during the IMRT. There was a significant reduction in Vp and D99 but not in HI in the 4D simulation in free-breathing and multiple fractions compared to the clinically-used plan (P < 0.05) suggesting that interplay effects deteriorate the dose distribution. The absolute difference of D99 was less than 1% of the prescribed dose. CONCLUSIONS: There were significant interplay effects affecting the dose distribution in stomach IMRT. The magnitude of the dose reduction was small when patients were treated on free-breathing and multiple fractions.

Machine-Learning-Based Prediction of Treatment Outcomes Using MR Imaging-Derived Quantitative Tumor Information in Patients with Sinonasal Squamous Cell Carcinomas: A Preliminary Study.
Noriyuki Fujima, Yukie Shimizu, Daisuke Yoshida, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Koichi Yasuda, Rikiya Onimaru, Osamu Sakai, Kohsuke Kudo, Hiroki Shirato
Cancers, 11, 6, 2019年06月10日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The purpose of this study was to determine the predictive power for treatment outcome of a machine-learning algorithm combining magnetic resonance imaging (MRI)-derived data in patients with sinonasal squamous cell carcinomas (SCCs). Thirty-six primary lesions in 36 patients were evaluated. Quantitative morphological parameters and intratumoral characteristics from T2-weighted images, tumor perfusion parameters from arterial spin labeling (ASL) and tumor diffusion parameters of five diffusion models from multi-b-value diffusion-weighted imaging (DWI) were obtained. Machine learning by a non-linear support vector machine (SVM) was used to construct the best diagnostic algorithm for the prediction of local control and failure. The diagnostic accuracy was evaluated using a 9-fold cross-validation scheme, dividing patients into training and validation sets. Classification criteria for the division of local control and failure in nine training sets could be constructed with a mean sensitivity of 0.98, specificity of 0.91, positive predictive value (PPV) of 0.94, negative predictive value (NPV) of 0.97, and accuracy of 0.96. The nine validation data sets showed a mean sensitivity of 1.0, specificity of 0.82, PPV of 0.86, NPV of 1.0, and accuracy of 0.92. In conclusion, a machine-learning algorithm using various MR imaging-derived data can be helpful for the prediction of treatment outcomes in patients with sinonasal SCCs.

[A Nutritional Supplement with a High Blend Ratio of ω-3 Fatty Acids(Prosure®) Reduces Severe Oral Mucositis and Body Weight Loss for Head and Neck Cancer Patients Treated with Chemoradiotherapy].
Mizumachi T, Kano S, Homma A, Akazawa M, Hasegawa C, Shiroishi Y, Okamoto C, Kumagai S, Nishimura M, Takasaki H, Takeda H, Yasuda K, Minatogawa H, Dekura Y, Onimaru R, Shirato H, Fukuda S
Gan to kagaku ryoho. Cancer & chemotherapy, 46, 4, 685, 689, 2019年04月, ［国内誌］
日本語, BACKGROUND: Oral mucositis and body weight loss are the most critical conditions known to lead to the discontinuation of chemoradiotherapy for head and neck cancer. We investigated the effect of a nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)on body weight loss, oral mucositis, and the completion rate of chemoradiotherapy in patients with oropharyngeal and hypopharyngeal cancer. PATIENTS AND METHODS: The study group comprised patients with oropharyngeal and hypopharyngeal cancer who were treated with concomitant cisplatin and 70 Gy of radiotherapy. These patients received 2 packs of Prosure®per day during chemoradiotherapy. RESULTS: A total of 17 patients were included in this study. The reduction in body weight was significantly improved compared with that in the historical control group that did not receive Prosure®(7.3% vs 10.3%, p<0.01), and the rate of Grade 3-4 oral mucositis was significantly reduced for the patient groups that received Prosure®(CTCAE v3.0 GradeB3; 24% vs 58%, p<0.05). The completion rate of chemoradiotherapy was not significantly different between both groups(77% vs 60%, NS). CONCLUSIONS: A nutritional supplement with a high blend ratio of w-3 fatty acids(Prosure®)had effects on oral mucositis and body weight loss in head and neck cancer patients treated with chemoradiotherapy.

Automatic metastatic bone tumor classification with DCNN-based features using treatment-planning CT
Haruna Watanabe, Ren Togo, Takahiro Ogawa, Miki Haseyama, Koichi Yasuda, Khin Khin Tha, Kohsuke Kudo, Hiroki Shirato
Proceedings of SPIE - The International Society for Optical Engineering, 11050, 2019年01月01日
研究論文（国際会議プロシーディングス）

Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients.
N Fujima, K Hirata, T Shiga, R Li, K Yasuda, R Onimaru, K Tsuchiya, S Kano, T Mizumachi, A Homma, K Kudo, H Shirato
Clinical radiology, 73, 12, 1059.e1-1059.e8, 2018年12月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, AIM: To assess potential prognostic factors in pharynx squamous cell carcinoma (SCC) patients by quantitative morphological and intratumoural characteristics obtained by 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (FDG-PET/CT). MATERIALS AND METHODS: The cases of 54 patients with pharynx SCC who underwent chemoradiation therapy were analysed retrospectively. Using their FDG-PET data, the quantitative morphological and intratumoural characteristics of 14 parameters were calculated. The progression-free survival (PFS) and overall survival (OS) information was obtained from patient medical records. Univariate and multivariate analyses were performed to assess the 14 quantitative parameters as well as the T-stage, N-stage, and tumour location data for their relation to PFS and OS. When an independent predictor was suggested in the multivariate analysis, the parameter was further assessed using the Kaplan-Meier method. RESULTS: In the assessment of PFS, the univariate and multivariate analyses indicated the following as independent predictors: the texture parameter of homogeneity and the morphological parameter of sphericity. In the Kaplan-Meier analysis, the PFS rate was significantly improved in the patients who had both a higher value of homogeneity (p=0.01) and a higher value of sphericity (p=0.002). With the combined use of homogeneity and sphericity, the patients with different PFS rates could be divided more clearly. CONCLUSION: The quantitative parameters of homogeneity and sphericity obtained by FDG-PET can be useful for the prediction of the PFS of pharynx SCC patients, especially when used in combination.

Intensity-Modulated Proton Therapy with Dose Painting based on Hypoxia Imaging for Nasopharyngeal Cancer
K. Yasuda, S. Takao, Y. Matsuo, T. Yoshimura, M. Tamura, H. Minatogawa, Y. Dekura, T. Matsuura, R. Onimaru, T. Shiga, S. Shimizu, K. Umegaki, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 102, 3, e378, e378, Elsevier BV, 2018年11月
研究論文（学術雑誌）

Semi-quantitative analysis of pre-treatment morphological and intratumoral characteristics using 18F-fluorodeoxyglucose positron-emission tomography as predictors of treatment outcome in nasal and paranasal squamous cell carcinoma.
Noriyuki Fujima, Kenji Hirata, Tohru Shiga, Koichi Yasuda, Rikiya Onimaru, Kazuhiko Tsuchiya, Satoshi Kano, Takatsugu Mizumachi, Akihiro Homma, Kohsuke Kudo, Hiroki Shirato
Quantitative imaging in medicine and surgery, 8, 8, 788, 795, 2018年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system.
Kentaro Nishioka, Anussara Prayongrat, Kota Ono, Shunsuke Onodera, Takayuki Hashimoto, Norio Katoh, Tetsuya Inoue, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Rikiya Onimaru, Hiroki Shirato, Shinichi Shimizu
Journal of radiation research, 59, suppl_1, i63-i71, i71, 2018年03月01日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors.
Yukiko Nishikawa, Koichi Yasuda, Shozo Okamoto, Yoichi M Ito, Rikiya Onimaru, Tohru Shiga, Kazuhiko Tsuchiya, Shiro Watanabe, Wataru Takeuchi, Yuji Kuge, Hao Peng, Nagara Tamaki, Hiroki Shirato
Radiation oncology (London, England), 12, 1, 148, 148, 2017年09月06日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）

The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Shozo Okamoto, Tohru Shiga, Koichi Yasuda, Shiro Watanabe, Kenji Hirata, Ken-Ichi Nishijima, Keiichi Magota, Katsuhiko Kasai, Rikiya Onimaru, Kazuhiko Tuchiya, Yuji Kuge, Hiroki Shirato, Nagara Tamaki
European journal of nuclear medicine and molecular imaging, 43, 12, 2147, 2154, 2016年11月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Effectiveness of superselective intra-arterial chemoradiotherapy targeting retropharyngeal lymph node metastasis.
Takayoshi Suzuki, Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Fumiyuki Suzuki, Satoshi Fukuda
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 273, 10, 3331, 6, 2016年10月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

A Retrospective Study of G-Tube Use in Japanese Patients Treated with Concurrent Chemoradiotherapy for Hypopharyngeal Cancer.
Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Tomohiro Sakashita, Rinnosuke Kuramoto, Yuji Nakamaru, Rikiya Onimaru, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
PloS one, 11, 8, e0161734, 2016年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Clinical outcomes of weekly cisplatin chemoradiotherapy for patients with pyriform sinus cancer.
Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
International journal of clinical oncology, 20, 6, 1081, 5, 2015年12月, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）

Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer.
Jun Furusawa, Akihiro Homma, Rikiya Onimaru, Tomohiro Sakashita, Daisuke Yoshida, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
Auris, nasus, larynx, 42, 6, 443, 8, 2015年12月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Akihiro Homma, Yuji Nakamaru, Tomohiro Sakashita, Rikiya Onimaru, Shunsuke Terasaka, Kazuhiko Tsuchiya, Daisuke Yoshida, Koichi Yasuda, Hiromitsu Hatakeyama, Jun Furusawa, Takatsugu Mizumachi, Satoshi Kano, Hiroki Shirato, Satoshi Fukuda
Auris, nasus, larynx, 42, 5, 377, 81, 2015年10月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

The efficacy of superselective intra-arterial infusion with concomitant radiotherapy for adenoid cystic carcinoma of the head and neck.
Akihiro Homma, Tomohiro Sakashita, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Yuji Nakamaru, Daisuke Yoshida, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
Acta oto-laryngologica, 135, 9, 950, 4, 2015年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Jun Furusawa, Satoshi Kano, Takatsugu Mizumachi, Satoshi Iizuka, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
Acta oto-laryngologica, 135, 8, 853, 8, 2015年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Takatsugu Mizumachi, Akihiro Homma, Tomohiko Kakizaki, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Kazuhiko Tsuchiya, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita, Hirotoshi Akita, Satoshi Fukuda
International journal of clinical oncology, 20, 3, 431, 7, 2015年06月, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）

Olfactory neuroblastoma: the long-term outcome and late toxicity of multimodal therapy including radiotherapy based on treatment planning using computed tomography.
Takashi Mori, Rikiya Onimaru, Shunsuke Onodera, Kazuhiko Tsuchiya, Koichi Yasuda, Hiromitsu Hatakeyama, Hiroyuki Kobayashi, Shunsuke Terasaka, Akihiro Homma, Hiroki Shirato
Radiation oncology (London, England), 10, 1, 88, 88, 2015年04月15日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

The incidence of late neck recurrence in N0 maxillary sinus squamous cell carcinomas after superselective intra-arterial chemoradiotherapy without prophylactic neck irradiation.
Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Jun Furusawa, Daisuke Yoshida, Noriyuki Fujima, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 271, 10, 2767, 70, 2014年10月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
Chowdhury Nusrat Fatema, Songji Zhao, Yan Zhao, Wenwen Yu, Ken-ichi Nishijima, Koichi Yasuda, Yoshimasa Kitagawa, Nagara Tamaki, Yuji Kuge
BMC cancer, 14, 692, 692, 2014年09月22日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Salvage operations for patients with persistent or recurrent cancer of the maxillary sinus after superselective intra-arterial infusion of cisplatin with concurrent radiotherapy
Sakashita T, Homma A, Hatakeyama H, Kano S, Mizumachi T, Furusawa J, Yoshida D, Fujima N, Onimaru R, Tsuchiya K, Yasuda K, Shirato H, Suzuki F, Fukuda S
Br J Oral Maxillofac Surg, 52, 4, 323, 8, 2014年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer
Homma A, Sakashita T, Yoshida D, Onimaru R, Tsuchiya K, Suzuki F, Yasuda K, Hatakeyama H, Furusawa J, Mizumachi T, Kano S, Inamura N, Taki S, Shirato H, Fukuda S
Br J Cancer, 109, 12, 2980, 2986, 2013年12月, ［査読有り］
英語

Evaluation of inter-observer variability of bladder boundary delineation on cone-beam CT.
Kentaro Nishioka, Shinichi Shimizu, Rumiko Kinoshita, Tetsuya Inoue, Shunsuke Onodera, Koichi Yasuda, Keiichi Harada, Yukiko Nishikawa, Rikiya Onimaru, Hiroki Shirato
Radiation oncology (London, England), 8, 185, 185, 2013年07月23日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
Tomohiro Sakashita, Akihiro Homma, Nobuhiko Oridate, Seigo Suzuki, Hiromitsu Hatakeyama, Satoshi Kano, Takatsugu Mizumachi, Rikiya Onimaru, Kazuhiko Tsuchiya, Koichi Yasuda, Hiroki Shirato, Satoshi Fukuda
Auris, nasus, larynx, 40, 2, 211, 5, 2013年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Shozo Okamoto, Tohru Shiga, Koichi Yasuda, Yoichi M Ito, Keiichi Magota, Katsuhiko Kasai, Yuji Kuge, Hiroki Shirato, Nagara Tamaki
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54, 2, 201, 7, 2013年02月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

[18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer
Yasuda K, Onimaru R, Okamoto S, Shiga T, Katoh N, Tsuchiya K, Suzuki R, Takeuchi W, Kuge Y, Tamaki N, Shirato H
Int J Radiat Oncol Biol Phys, 85, 1, 142, 7, 2013年, ［査読有り］, ［筆頭著者］

A new brain positron emission tomography scanner with semiconductor detectors for target volume delineation and radiotherapy treatment planning in patients with nasopharyngeal carcinoma.
Norio Katoh, Koichi Yasuda, Tohru Shiga, Masakazu Hasegawa, Rikiya Onimaru, Shinichi Shimizu, Gerard Bengua, Masayori Ishikawa, Nagara Tamaki, Hiroki Shirato
International journal of radiation oncology, biology, physics, 82, 4, e671-6, E676, 2012年03月15日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy.
Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, Fujiwara M, Shioyama Y, Kagami Y, Shibamoto Y, Nakata K, Takada Y, Kawabe T, Uehara K, Nibu K, Yamada S
International journal of radiation oncology， biology， physics, 82, 2, 626, 34, 2012年02月01日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Accurate analysis of the change in volume, location, and shape of metastatic cervical lymph nodes during radiotherapy.
Takao S, Tadano S, Taguchi H, Yasuda K, Onimaru R, Ishikawa M, Bengua G, Suzuki R, Shirato H
Int J Radiat Oncol Biol Phys, 81, 3, 871, 9, 2011年11月01日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Concomitant weekly cisplatin and radiotherapy for head and neck cancer.
Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, Kano S, Sakashita T, Onimaru R, Yasuda K, Shirato H, Fukuda S
Jpn J Clin Oncol, 41, 8, 980, 6, 2011年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Relationship between diseased lung tissues on computed tomography and motion of fiducial marker near lung cancer.
Onodera Y, Nishioka N, Yasuda K, Fujima N, Torres M, Kamishima T, Ooyama N, Onimaru R, Terae S, Ooizumi S, Nishimura M, Shirato H
Int J Radiat Oncol Biol Phys, 79, 5, 1408, 13, 2011年04月01日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Long-term outcomes of fractionated stereotactic radiotherapy for intracranial skull base benign meningiomas in single institution.
Onodera S, Aoyama H, Katoh N, Taguchi H, Yasuda K, Yoshida D, Surtherland K, Suzuki R, Ishikawa M, Gerard B, Terasaka S, Shirato H
Japanese journal of clinical oncology, 41, 4, 462, 468, 4, 2011年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: To investigate the outcome of linac-based fractionated stereotactic radiotherapy over the last 10 years for intracranial skull base benign meningiomas in patients who were inoperable, who had residual tumors with some components of high mitotic index after surgery and who experienced relapse of the tumor. METHODS: Twenty-seven patients with intracranial skull base benign meningiomas treated with fractionated stereotactic radiotherapy were retrospectively reviewed. Twenty-seven cases were diagnosed as benign meningiomas on pathological (17 cases) or radiological (10 cases) examination. The median follow-up time was 90 months after initial treatment and 63 months after fractionated stereotactic radiotherapy. The median biological equivalent dose calculated using an α/β ratio of 2.0 Gy was 82.0 Gy (range, 60-106 Gy). RESULTS: The 5-year overall survival was 95.7 (95% confidence interval: 87.3-100)% after initial treatment and 96.2 (88.8-100)% after fractionated stereotactic radiotherapy. The 5-year overall survival and local control rate of patients who received fractionated stereotactic radiotherapy alone were both 100%. The 5-year progression-free survival and local control rate after fractionated stereotactic radiotherapy were all 100% with a tumor volume of <9.1 cc and 68.2 (37.2-99.2) and 75.8 (45.2-100)% for the tumors 9.1 cc, respectively. The difference was significant in progression-free survival (P = 0.022) and local control rate (P = 0.044). The local control rate was significantly worse in patients who received fractionated stereotactic radiotherapy for relapsed tumors (P = 0.01). No late radiation damage was observed in the follow-up period. CONCLUSIONS: The long-term outcome suggests that fractionated stereotactic radiotherapy is a safe and effective treatment for intracranial skull base benign meningioma, especially for those who have tumors <9.1 cc or would receive fractionated stereotactic radiotherapy with or without surgery as the initial treatment.

Radiotherapy for glottic T1N0 carcinoma with slight hypofractionation and standard overall treatment time: importance of overall treatment time.
Onimaru R, Hasegawa M, Yasuda K, Homma A, Oridate N, Fukuda S, Shirato H
Jpn J Clin Oncol, 41, 1, 103, 9, 1, 2011年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: We retrospectively investigated treatment outcomes in patients with glottic T1 carcinoma treated with 65 Gy in 26 fractions four times a week and discuss the importance of the overall treatment time. METHODS: Two hundred one patients with glottic T1 carcinoma were evaluated. Sixty-five Gray in 26 fractions were delivered for 200 patients, whereas 1 patient received 62.5 Gy in 25 fractions. We delivered radiotherapy once daily four times a week in this period, for a weekly dose of 10 Gy. Weekdays except Wednesday were treatment days. RESULTS: The overall survival rate was 96.8 ± 1.3% (standard error) at 3 years and 90.8 ± 2.2% at 5 years. The local control rate was 91.9 ± 2.0% at 3 years and 89.8 ± 2.3% at 5 years. In patients with an overall treatment time equal to or longer than 47 days, the local control rate was 82.6 ± 6.0% at both 3 and 5 years. In the patients with overall treatment time equal to or less than 46 days, the local control rate was 94.6 ± 1.9% at 3 years and 91.8 ± 2.4% at 5 years. There was a significant difference between these two groups (P = 0.0349). A severe late radiation reaction occurred in one patient. He experienced severe laryngeal edema that required tracheotomy at 6 months after the completion of radiotherapy. The tracheotomy was closed at 14 months after completion of radiotherapy. CONCLUSIONS: Overall treatment time seems to be an important factor for a good local control rate for glottic T1N0 carcinoma even when treated with slight hypofractionation.

Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Koichi Yasuda, Hiroshi Taguchi, Yutaka Sawamura, Jun Ikeda, Hidefumi Aoyama, Kenji Fujieda, Nobuaki Ishii, Masaaki Kashiwamura, Yoshinobu Iwasaki, Hiroki Shirato
Japanese journal of clinical oncology, 38, 7, 486, 92, 2008年07月, ［査読有り］, ［筆頭著者］, ［国際誌］
英語, 研究論文（学術雑誌）

A new positron emission tomography with semiconductor detectors for target volume delineation and radiotherapy treatment planning in patients with nasopharyngeal carcinoma
N. Katoh, T. Shiga, M. Hasegawa, R. Onimaru, K. Yasuda, S. Shimizu, G. Bengua, M. Ishikawa, N. Tamaki, H. Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72, 1, S589, S590, 2008年, ［査読有り］
英語

咽喉頭癌の高精度放射線治療における治療途中の線量分布評価および放射線治療計画変更に関する解析
高橋周平, 安田耕一, 服部敬寛, 小泉富基, 井戸川寛志, 鈴木崇祥, 対馬那由多, 加納里志, 本間明宏, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年

鼻副鼻腔悪性腫瘍に対する高精度放射線治療後の晩期障害
安田耕一, 高橋周平, 宮崎智彦, 服部敬寛, 檜垣朔, 小泉富基, 対馬那由多, 加納里志, 本間明宏, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年

多発脳転移に対するSingle Isocenter Multi Target-VMATを用いた定位放射線治療の短期治療成績と,微小病変に対する線量低減の試み
西岡健太郎, 西岡健太郎, RUJA Vichitvejpaisal, 森崇, 山田亮太, 高橋周平, 小泉富基, 安田耕一, 加藤徳雄, 加藤徳雄, 橋本孝之, 橋本孝之, 青山英史, 青山英史, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年

耳鼻咽喉科・頭頸部外科領域 12 頭頸部腫瘍 上咽頭がん
安田耕一, 耳鼻咽喉科・頭頚部外科, 97, 5, 2025年

唾液腺癌の局所頸部制御における術後照射の有用性の検討
加納里志, 対馬那由多, 鈴木崇祥, 浜田誠二郎, 安田耕一, 打浪雄介, 本間明宏, 頭頸部癌, 50, 1, 2024年

局所進行HER2陽性唾液腺癌に対してトラスツズマブ+ドセタキセル併用療法が導入化学療法/術前化学療法として有効であった2症例
加納里志, 対馬那由多, 鈴木崇祥, 井戸川寛志, 勝俣量平, 安田耕一, 清水康, 田口純, 多田雄一郎, 本間明宏, 日本唾液腺学会誌, 64, 2024年

次世代シークエンサーによる鼻副鼻腔粘膜悪性黒色腫の遺伝子発現解析
対馬那由多, 加納里志, 鈴木崇祥, 浜田誠二郎, 安田耕一, 清水康, 田口純, 本間明宏, 頭頸部癌, 49, 2, 2023年

高齢者の局所進行頭頸部扁平上皮癌患者におけるweeklyシスプラチン併用放射線治療の治療成績
打浪雄介, 安田耕一, 加納里志, 対馬那由多, 鈴木崇祥, 浜田誠二郎, 田口純, 清水康, 坂下智博, 本間明宏, 頭頸部癌, 49, 2, 2023年

当院で治療した頭頸部原発横紋筋肉腫症例の検討
勝俣量平, 勝俣量平, 加納里志, 対馬那由多, 鈴木崇祥, 浜田誠二郎, 清水康, 田口純, 安田耕一, 打浪雄介, 本間明宏, 頭頸部癌, 49, 2, 2023年

高齢者の頭頸部癌に対する放射線治療と化学療法併用の実態:日本頭頸部癌学会悪性腫瘍全国登録調査の解析
安田耕一, 打浪雄介, 加納里志, 田口純, 清水康, 本間明宏, 頭頸部癌, 49, 2, 2023年

唾液腺癌の局所頸部制御における術後照射の有用性の検討
加納里志, 対馬那由多, 鈴木崇祥, 浜田誠二郎, 安田耕一, 打浪雄介, 本間明宏, 頭頸部癌, 49, 2, 2023年

局所進行甲状腺分化癌に対する術後補助療法の治療開発と全国実態調査
川本晃史, 川本晃史, 安田耕一, 伊藤芳紀, 全田貞幹, 坂中克行, 鹿間直人, 中村直樹, 溝脇尚志, 日本甲状腺学会学術集会プログラム・抄録集(Web), 66th, 2023年

適応陽子線治療における日々の線量分布の迅速評価システムの開発
小橋啓司, 小橋啓司, 西岡健太郎, 西岡健太郎, 橋本孝之, 橋本孝之, 田村弘詞, 中里慧二, 田口大志, 安田耕一, 安田耕一, 打浪雄介, 打浪雄介, 加藤徳雄, 加藤徳雄, 青山英史, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 36th, 2023年

【がん免疫療法の展望:免疫チェックポイント阻害薬の併用療法に中心に】免疫チェックポイント阻害薬の併用療法のエビデンス 免疫チェックポイント阻害薬と放射線治療
安田 耕一, 志藤 元泰, 小泉 富基, 高橋 周平, 藤田 祥博, 大塚 愛美, 宮崎 智彦, 西川 昇, 打浪 雄介, 森 崇, 西岡 健太郎, 木下 留美子, 田口 大志, 加藤 徳雄, 橋本 孝之, 青山 英史, 腫瘍内科, 30, 1, 23, 28, 2022年07月
(有)科学評論社, 日本語

高齢者(特に80歳以上)頭頸部癌の治療戦略-何を指標にどのように治療を行うか- 高齢者頭頸部癌の放射線治療
安田 耕一, 頭頸部癌, 48, 2, 140, 140, 2022年05月
(一社)日本頭頸部癌学会, 日本語

咽喉頭癌に対するシスプラチン超選択的動注併用放射線治療(RADPLAT)による頸部制御の検討
加納 里志, 対馬 那由多, 鈴木 崇祥, 浜田 誠二郎, 吉田 大介, 打浪 雄介, 安田 耕一, 本間 明宏, 頭頸部癌, 48, 2, 151, 151, 2022年05月
(一社)日本頭頸部癌学会, 日本語

高齢の頭頸部悪性腫瘍に対する放射線治療の後ろ向き検討
安田 耕一, 打浪 雄介, 浜田 誠二郎, 鈴木 崇祥, 対馬 那由多, 田口 純, 清水 康, 加納 里志, 本間 明宏, 頭頸部癌, 48, 2, 200, 200, 2022年05月
(一社)日本頭頸部癌学会, 日本語

局所進行上咽頭癌におけるadaptive radiotherapyに関する検討
打浪雄介, 安田耕一, 藤田祥博, 高橋周平, 大塚愛美, 田口純, 清水康, 加納里志, 本間明宏, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 35th, 2022年

強度変調放射線治療(IMRT)を行った下咽頭癌における再発症例の検討
大塚愛美, 安田耕一, 湊川英樹, 出倉康裕, 青山英史, 清水伸一, 鈴木隆介, 宮本直樹, 清水伸一, 鈴木崇祥, 対馬那由多, 加納里志, 田口純, 清水康, 本間明宏, 清水伸一, Japanese Journal of Radiology, 40, Supplement, 2022年

ここが変わった!頭頸部癌診療ガイドライン2022 上咽頭癌
安田耕一, 耳鼻咽喉科・頭頚部外科, 94, 11, 2022年

再照射 小児がんに対する陽子線再照射
橋本 孝之, 森 崇, 西岡 健太郎, 打浪 雄介, 安田 耕一, 木下 留美子, 田口 大志, 加藤 徳雄, 清水 伸一, 青山 英史, 日本小児血液・がん学会雑誌, 58, 2, 89, 93, 2021年08月
(一社)日本小児血液・がん学会, 日本語

放射線治療
安田 耕一, 耳鼻咽喉科臨床 補冊, 補冊157, 43, 43, 2021年06月
耳鼻咽喉科臨床学会, 日本語

咽喉頭扁平上皮癌IMRTの照射中における線量分布変化に関する解析
安田 耕一, 打浪 雄介, 湊川 英樹, 小泉 富基, 大塚 愛美, 藤田 祥博, 井戸川 寛志, 鈴木 崇祥, 対馬 那由多, 加納 里志, 本間 明宏, 頭頸部癌, 47, 2, 210, 210, 2021年05月
(一社)日本頭頸部癌学会, 日本語

CCRTを施行した頭頸部癌患者に対する予防的胃瘻増設の有用性の検討
加納 里志, 対馬 那由多, 鈴木 崇祥, 井戸川 寛志, 浜田 誠二郎, 横川 泰三, 安田 耕一, 湊川 英樹, 打浪 雄介, 本間 明宏, 頭頸部癌, 47, 2, 211, 211, 2021年05月
(一社)日本頭頸部癌学会, 日本語

SMARCB1欠損篩骨洞癌に対する強度変調陽子線治療 症例報告と文献レビュー
宮崎 智彦, 安田 耕一, 志藤 元泰, 小泉 富基, 藤田 祥博, 高橋 周平, 湊川 英樹, 大塚 愛美, 加藤 徳雄, 清水 伸一, 青山 英史, 北海道放射線医学雑誌, 1, 1, 6, 2021年03月
(NPO)メディカルイメージラボ, 日本語

強度変調放射線療法(IMRT)による下咽頭癌の失敗と晩期毒性のパターン:遡及的分析
OTSUKA Manami, YASUDA Koichi, MINATOGAWA Hideki, DEKURA Yasuhiro, KOIZUMI Fuki, SUZUKI Ryusuke, SHIMIZU Yasushi, HOMMA Akihiro, SHIMIZU Shinichi, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 80th, 2021年

嗅神経芽細胞腫に対する強度変調放射線療法の治療成績
MORI Takashi, MINATOGAWA Hideki, YASUDA Koichi, KOIZUMI Fuki, OTSUKA Manami, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 80th, 2021年

小児がんに対する陽子線再照射
橋本孝之, 森崇, 西岡健太郎, 打浪雄介, 安田耕一, 木下留美子, 田口大志, 加藤徳雄, 清水伸一, 青山英史, 日本小児血液・がん学会雑誌(Web), 58, 2, 2021年

肝細胞癌陽子線治療前MRIにおけるばらつきの小さいADC値指標の検討:治療効果予測に向けた前段階の研究
藤田祥博, 加藤徳雄, 田口大志, 打浪雄介, 西岡健太郎, 森崇, 湊川英樹, 安田耕一, 清水伸一, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 34th, 2021年

頭皮原発血管肉腫に対する化学療法および強度変調放射線照射による集学的治療の有用性
前田 拓, 北條 正洋, 林 利彦, 山本 有平, 安田 耕一, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 36回, 153, 153, 2020年12月
(一社)日本皮膚悪性腫瘍学会, 日本語

頭皮原発血管肉腫に対する化学療法および強度変調放射線照射による集学的治療の有用性
前田 拓, 北條 正洋, 林 利彦, 山本 有平, 安田 耕一, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 36回, 153, 153, 2020年12月
(一社)日本皮膚悪性腫瘍学会, 日本語

画像誘導治療の今後について 画像誘導陽子線治療の将来展望　　　　　　　　　　　　　　　
田口 大志, 橋本 孝之, 加藤 徳雄, 木下 留美子, 安田 耕一, 西岡 健太郎, 森 崇, 打浪 雄介, 宮本 直樹, 高尾 聖心, 清水 伸一, 青山 英史, 日本癌治療学会学術集会抄録集, 58回, SY14, 3, 2020年10月
(一社)日本癌治療学会, 英語

上・中・下咽頭癌に対する陽子線治療の初期経験
安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史, 頭頸部癌, 46, 2, 161, 161, 2020年07月
(一社)日本頭頸部癌学会, 日本語

休日による総治療期間延長に対して1回線量増加の方法を組み合わせて放射線治療を行った早期声門癌の検討
出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 鬼丸 力也, 本間 明宏, 青山 英史, 頭頸部癌, 46, 2, 179, 179, 2020年07月
(一社)日本頭頸部癌学会, 日本語

頭頸部粘膜悪性黒色腫に対する術後陽子線治療30GyE/5回の初期経験
湊川 英樹, 安田 耕一, 出倉 康裕, 鈴木 正宣, 中丸 裕爾, 中薗 彬, 鈴木 崇祥, 対馬 那由多, 加納 里志, 鬼丸 力也, 清水 伸一, 本間 明宏, 青山 英史, 頭頸部癌, 46, 2, 188, 188, 2020年07月
(一社)日本頭頸部癌学会, 日本語

Head and Neck Tumor 頭頸部腫瘍 頭頸部癌再発症例への対応 II.切除不能例への対応-放射線治療-
安田耕一, 安田耕一, 癌と化学療法, 47, 7, 2020年

薬物療法および強度変調放射線照射による集学的治療が奏功した頭皮原発血管肉腫の治療経験
前田拓, 北條正洋, 林利彦, 石川耕資, 大澤昌之, 舟山恵美, 山本有平, 安田耕一, 湊川英樹, 日本頭蓋顎顔面外科学会学術集会プログラム・抄録集, 38th, 2020年

頭部血管肉腫に対するIMRTの治療経験
北條正洋, 林利彦, 村尾尚規, 前田拓, 鬼丸力也, 安田耕一, 山本有平, 日本形成外科学会総会・学術集会プログラム・抄録集, 63rd (CD-ROM), 2020年

画像誘導陽子線治療の将来展望
田口大志, 橋本孝之, 橋本孝之, 加藤徳雄, 木下留美子, 安田耕一, 西岡健太郎, 西岡健太郎, 森崇, 打浪雄介, 宮本直樹, 高尾聖心, 清水伸一, 清水伸一, 青山英史, 日本癌治療学会学術集会(Web), 58th, 2020年

当科における局所進行外耳道扁平上皮癌の治療成績の検討
加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 対馬 那由多, 鈴木 崇祥, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 頭頸部癌, 45, 3, 300, 304, 2019年10月
(一社)日本頭頸部癌学会, 日本語

乳癌に対するコーンビームCTによる患者セットアップ精度の評価
谷井 大介, 安田 耕一, 細木 和則, 小澤 公太, 蛯名 慶也, 岩井 良夫, 共済医報, 68, Suppl., 114, 114, 2019年10月
国家公務員共済組合連合会, 日本語

脾臓への放射線照射が奏功した脾機能亢進症の1例
岩崎 愛美, 安田 耕一, 遠藤 知之, 大東 寛幸, 清水 伸一, 鬼丸 力也, 豊嶋 崇徳, 白土 博樹, 日本医学放射線学会秋季臨床大会抄録集, 55回, S518, S518, 2019年09月
(公社)日本医学放射線学会, 日本語

強度変調X線治療および強度変調陽子線治療における皮膚炎と皮膚線量に関する検討
安田 耕一, 湊川 英樹, 出倉 康裕, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹, 頭頸部癌, 45, 2, 134, 134, 2019年05月
(一社)日本頭頸部癌学会, 日本語

外耳道癌における強度変調陽子線治療と強度変調X線治療との線量分布の比較
出倉 康裕, 安田 耕一, 湊川 英樹, 対馬 那由多, 鈴木 崇祥, 加納 里志, 水町 貴諭, 鬼丸 力也, 清水 伸一, 本間 明宏, 白土 博樹, 頭頸部癌, 45, 2, 138, 138, 2019年05月
(一社)日本頭頸部癌学会, 日本語

頭頸部癌化学放射線療法におけるEPA高配合栄養機能食品(プロシュア)の有用性の検討
水町 貴諭, 加納 里志, 本間 明宏, 赤澤 美樹子, 長谷川 千春, 城石 陽子, 岡本 千秋, 熊谷 聡美, 西村 雅勝, 高崎 裕代, 武田 宏司, 安田 耕一, 湊川 英樹, 出倉 康裕, 鬼丸 力也, 白土 博樹, 福田 諭, 癌と化学療法, 46, 4, 685, 689, 2019年04月
(株)癌と化学療法社, 日本語

強度変調放射線治療中に皮下気腫をきたし,再検証を要した頭頸部癌患者の1例　　　　　　　　　　　　　　　
湊川 英樹, 安田 耕一, 白土 博樹, 土屋 和彦, 鈴木 隆介, 宮本 直樹, 坂下 智博, 本間 明宏, 福田 諭, Japanese Journal of Radiology, 37, Suppl., 4, 4, 2019年02月
(公社)日本医学放射線学会, 日本語

頭頸部癌患者の口腔支持療法と地域連携
秦 浩信, 吉川 和人, 今待 賢治, 村井 知佳, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政, 頭頸部癌, 44, 4, 380, 386, 2018年12月
(一社)日本頭頸部癌学会, 日本語

深層学習に基づく画像特徴量を利用した放射線治療用CT画像における転移性骨腫瘍の検出に関する検討
渡邊はるな, 藤後廉, 小川貴弘, 長谷山美紀, 安田耕一, THA Khin Khin, 工藤與亮, 白土博樹, 電気・情報関係学会北海道支部連合大会講演論文集(CD-ROM), 2018, ROMBUNNO.87, 2018年10月27日
日本語

喉頭癌cT3の喉頭温存治療(CRT vs RADPLAT) 喉頭癌に対する超選択的動注と放射線同時併用療法
本間 明宏, 加納 里志, 水町 貴諭, 中薗 彬, 鈴木 崇祥, 坂下 智博, 福田 諭, 鬼丸 力也, 安田 耕一, 湊川 英樹, 出倉 康裕, 土屋 和彦, 白土 博樹, 日本気管食道科学会会報, 69, 5, 319, 320, 2018年10月
(NPO)日本気管食道科学会, 日本語

【核医学の放射線治療への新規応用】PETの放射線治療への応用 特に頭頸部癌に関して
安田 耕一, 臨床放射線, 63, 9, 961, 967, 2018年09月
金原出版(株), 日本語

Quality of Survivalを考慮した頭頸部癌支持療法 頭頸部がん患者の口腔支持療法と地域連携
秦 浩信, 吉川 和人, 今待 賢治, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政, 頭頸部癌, 44, 2, 115, 115, 2018年05月
(一社)日本頭頸部癌学会, 日本語

当科における局所進行外耳道扁平上皮癌の治療成績の検討
加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 頭頸部癌, 44, 2, 181, 181, 2018年05月
(一社)日本頭頸部癌学会, 日本語

Quality of Survivalを考慮した頭頸部癌支持療法 頭頸部がん患者の口腔支持療法と地域連携
秦 浩信, 吉川 和人, 今待 賢治, 上田 倫弘, 永橋 立望, 西山 典明, 安田 耕一, 本間 明宏, 北川 善政, 頭頸部癌, 44, 2, 115, 115, 2018年05月, ［査読有り］
(一社)日本頭頸部癌学会, 日本語

当科における局所進行外耳道扁平上皮癌の治療成績の検討
加納 里志, 森田 真也, 中丸 裕爾, 水町 貴諭, 中薗 彬, 福田 篤, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 頭頸部癌, 44, 2, 181, 181, 2018年05月, ［査読有り］
(一社)日本頭頸部癌学会, 日本語

同時期に異所性に発生した悪性腫瘍に対して、二部位同時にIMRTを施行した症例　　　　　　　　　　　　　　　
湊川 英樹, 安田 耕一, 白土 博樹, 土屋 和彦, 原田 八重, 水町 貴諭, 坂下 智博, 本間 明宏, 福田 諭, 石嶋 漢, 宮本 直樹, 高尾 聖心, 鈴木 隆介, 松浦 妙子, 牧永 綾乃, 田村 昌也, Japanese Journal of Radiology, 36, Suppl., 6, 6, 2018年02月
(公社)日本医学放射線学会, 日本語

乳癌眼窩尖部転移により視力低下をきたし、放射線治療により著明な改善を認めた1例　　　　　　　　　　　　　　　
湊川 英樹, 安田 耕一, 打浪 雄介, 白土 博樹, 土屋 和彦, 加藤 徳雄, 木下 留美子, 石田 直子, 山下 啓子, 石嶋 漢, Japanese Journal of Radiology, 36, Suppl., 11, 11, 2018年02月
(公社)日本医学放射線学会, 日本語

放射線治療における数値指標の医学物理的利用
清水伸一, 小橋啓司, 伊藤陽一, PRAYONGRAT Anussara, 加藤徳雄, 安田耕一, 出倉康裕, 木元拓也, 白土博樹, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 31st (CD-ROM), 39, 2018年
日本語

Analysis of Threshold Doses for Radiation Induced Liver Parenchymal Changes on MRI after Real TimeeImage Gated Spot-Scanning Proton Beam Therapy of Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, S. Takao, K. Yasuda, K. Harada, T. Inoue, T. Matsuura, T. Hashimoto, S. Shimizu, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E159, E160, 2017年10月
英語, 研究発表ペーパー・要旨（国際会議）

Can F-18-fluoromisonidazole PET/CT Predict the Clinical Outcome for Stage I Non-small Cell Lung Cancer Treated By Stereotactic Body Radiation Therapy?
T. Inoue, S. Watanabe, K. Harada, K. Yasuda, N. Katoh, S. Okamoto, T. Shiga, Y. Kuge, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E466, E466, 2017年10月
英語, 研究発表ペーパー・要旨（国際会議）

PETの放射線治療への応用 特に頭頸部癌に関して　　　　　　　　　　　　　　　
安田 耕一, 核医学, 54, Suppl., S139, S139, 2017年09月
(一社)日本核医学会, 日本語

分子イメージングを用いた放射線治療
安田 耕一, JSMI Report, 10, 2, 29, 32, 2017年05月
代表的な低酸素イメージングである[18F]fluoromisonidazole(FMISO)-PETを放射線治療に応用するためには、低酸素の領域を正確に同定する必要があり、高性能なPETが不可欠である。そのため新たな仕組みのPETが開発された。検出器にCdTe半導体を用いることでγ線を直接電気信号に変換することができ、検出器が小型化され、高い空間分解能を示している。1)FMISO-PET画像のコントラストと半導体PET、2)FMISO-PET画像の再現性、3)治療前FMISO-PETと再現部位の関係、4)頭頸部癌以外におけるFMISO-PETの応用、について述べた。, 日本分子イメージング学会, 日本語

甲状腺癌分化癌の骨転移に対するIMRTを含めた外照射の治療成績
安田 耕一, 加藤 徳雄, 岡本 祥三, 木下 留美子, 志賀 哲, 水町 貴諭, 畠山 博充, 本間 明宏, 田口 純, 清水 康, 森 崇, 土屋 和彦, 白土 博樹, 頭頸部癌, 43, 2, 221, 221, 2017年05月
(一社)日本頭頸部癌学会, 日本語

FMISO-PET during intensity-modulated radiotherapy can predict more accurately than pre-therapeutic and post-therapeutic PET for head and neck cancer.
Shozo Okamoto, Tohru Shiga, Koichi Yasuda, Shiro Watanabe, Keiichi Magota, Rikiya Onimaru, Kazuhiko Tsuchiya, Yuji Kuge, Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 58, 2017年05月, ［査読有り］
英語, 研究発表ペーパー・要旨（国際会議）

下咽頭癌に対する強度変調放射線治療(IMRT)と強度変調陽子線治療(IMPT)の治療計画の比較
土屋 和彦, 安田 耕一, 原田 八重, 鬼丸 力也, 白土 博樹, Japanese Journal of Radiology, 35, Suppl., 10, 10, 2017年02月
(公社)日本医学放射線学会, 日本語

PETの放射線治療への応用-特に頭頸部癌に関して-
安田耕一, 核医学(Web), 54, Supplement, 2017年

高次医療連携システムによる医療情報の有効活用について 患者と医療者のためのがん治療の道標の可視化 患者中心のがん診断・治療ナビゲーションシステム開発
白土 博樹, 安田 耕一, 熊木 康雄, 上杉 正人, 医療情報学連合大会論文集, 36回, 1, 126, 127, 2016年11月
(一社)日本医療情報学会, 日本語

気管内挿管下全身麻酔管理で陽子線治療を実施した小児がんの2症例(Proton beam therapy for pediatric cancer with endotracheal intubation under the general anesthesia: A report of two cases)
橋本 孝之, 敦賀 健吉, 小林 浩之, 井口 晶裕, 本多 昌平, 杉山 未奈子, 安田 耕一, 宮城 久之, 山口 秀, 藤田 憲明, 大島 淳二郎, 長 祐子, 鬼丸 力也, 清水 伸一, 寺坂 俊介, 森本 裕二, 白土 博樹, 日本小児血液・がん学会雑誌, 53, 4, 366, 366, 2016年11月
(NPO)日本小児血液・がん学会, 英語

患者中心のがん診断・治療ナビゲーションシステム開発
白土博樹, 安田耕一, 熊木康雄, 上杉正人, 医療情報学, 36, Supplement 1, 126‐127, 2016年11月01日
日本語

High Reproducibility of FMISO PET with high-definition semiconductor PET in patients with head and neck cancer.
Tohru Shiga, Shozo Okamoto, Wataru Takeuchi, Atsuro Suzuki, Koichi Yasuda, Keiichi Magota, Shiro Watanabe, Kenji Hirata, Yuji Kuge, Keiji Kobashi, Nagara Tamaki, JOURNAL OF NUCLEAR MEDICINE, 57, 2016年05月
英語, 研究発表ペーパー・要旨（国際会議）

上咽頭癌再発例におけるFMISO-PETと放射線治療に関する解析
安田 耕一, 西川 由記子, 岡本 祥三, 伊藤 陽一, 土屋 和彦, 志賀 哲, 鬼丸 力也, 久下 裕司, 玉木 長良, 白土 博樹, 頭頸部癌, 42, 2, 158, 158, 2016年05月
(一社)日本頭頸部癌学会, 日本語

中咽頭扁平上皮癌に対する化学放射線療法施行症例の臨床的検討
水町 貴諭, 坂下 智博, 加納 里志, 畠山 博充, 本間 明宏, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭, 頭頸部癌, 42, 2, 181, 181, 2016年05月
(一社)日本頭頸部癌学会, 日本語

下咽頭癌に対する化学放射線療法後の嚥下障害 欧米の報告との比較
本間 明宏, 畠山 博充, 水町 貴諭, 加納 里志, 坂下 智博, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭, 頭頸部癌, 42, 2, 214, 214, 2016年05月
(一社)日本頭頸部癌学会, 日本語

分子イメージングを用いた放射線治療
安田耕一, 安田耕一, 岡本祥三, 西川由記子, 伊藤陽一, 志賀哲, 井上哲也, 森崇, 豊永拓哉, 鬼丸力也, 渡邊史郎, 土屋和彦, 竹内渉, 加藤徳雄, 加藤徳雄, 久下裕司, 玉木長良, 白土博樹, 白土博樹, JSMI Report, 9, 2, 83, 83, 2016年04月25日
日本分子イメージング学会, 日本語

Clinical application for molecular imaging(Therapy) 分子イメージングを用いた放射線治療　　　　　　　　　　　　　　　
安田 耕一, 岡本 祥三, 西川 由記子, 伊藤 陽一, 志賀 哲, 井上 哲也, 森 崇, 豊永 拓哉, 鬼丸 力也, 渡邊 史郎, 土屋 和彦, 竹内 渉, 加藤 徳雄, 久下 裕司, 玉木 長良, 白土 博樹, JSMI Report, 9, 2, 83, 83, 2016年04月
日本分子イメージング学会, 日本語

当院における下咽頭癌に対する強度変調放射線治療(IMRT)の初期経験
土屋 和彦, 安田 耕一, 原田 八重, 鬼丸 力也, 白土 博樹, Japanese Journal of Radiology, 34, Suppl., 11, 11, 2016年02月
(公社)日本医学放射線学会, 日本語

椎体IMRTとその精度に関する研究
安田 耕一, 清水 伸一, 橋本 孝之, Sutherland Ken, 白土 博樹, 土屋 和彦, 加藤 徳雄, 鬼丸 力也, 木下 留美子, 井上 哲也, 西岡 健太郎, 西川 由記子, 森 崇, 原田 慶一, 原田 八重, 鈴木 隆介, 寅松 千枝, 松浦 妙子, 高尾 聖心, 宮本 直樹, 伊藤 陽一, Japanese Journal of Radiology, 34, Suppl., 5, 5, 2016年02月
(公社)日本医学放射線学会, 日本語

気管内挿管下全身麻酔管理で陽子線治療を実施した小児がんの2症例
橋本孝之, 敦賀健吉, 小林浩之, 井口晶裕, 本多昌平, 杉山未奈子, 安田耕一, 宮城久之, 山口秀, 藤田憲明, 大島淳二郎, 長祐子, 鬼丸力也, 清水伸一, 寺坂俊介, 森本裕二, 白土博樹, 日本小児血液・がん学会雑誌(Web), 53, 4, 2016年

下咽頭癌に対する超選択的動注併用放射線治療の適応
古沢 純, 本間 明宏, 鬼丸 力也, 坂下 智博, 吉田 大介, 畠山 博充, 水町 貴諭, 加納 里志, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭, 日本耳鼻咽喉科学会会報, 119, 5, 782, 783, 2016年
一般社団法人 日本耳鼻咽喉科学会, 日本語

Respiration-gated F-18-fluoromisonidazole PET/CT for Stage I Non-Small Cell Lung Cancer Treated by Stereotactic Body Radiation Therapy
T. Inoue, S. Okamoto, S. Watanabe, K. Yasuda, N. Katoh, K. Harada, R. Onimaru, T. Shiga, N. Tamaki, Y. Kuge, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E390, E391, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

The Voxel-based Analysis of FMISO-PET Image in Patients With Local Recurrence of Nasopharyngeal Carcinoma
Y. Nishikawa, K. Yasuda, S. Okamoto, Y. M. Ito, T. Mori, R. Onimaru, T. Shiga, K. Tsuchiya, S. Watanabe, W. Takeuchi, N. Katoh, Y. Kuge, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E337, E337, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

半導体PETを用いた頭頸部癌FMISO-PETの再現性
志賀 哲, 岡本 祥三, 安田 耕一, 孫田 恵一, 久下 裕司, 竹内 渉, 鈴木 敦郎, 小橋 啓司, 玉木 長良, 核医学, 52, 3, 265, 265, 2015年09月
(一社)日本核医学会, 日本語

当院における下咽頭癌に対する強度変調放射線治療(IMRT)の初期臨床成績
土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊, 頭頸部癌, 41, 2, 254, 254, 2015年05月
(一社)日本頭頸部癌学会, 日本語

当科における嗅神経芽細胞腫に対する放射線治療成績の検討
森 崇, 土屋 和彦, 西川 昇, 鬼丸 力也, 小野寺 俊輔, 安田 耕一, 白土 博樹, Japanese Journal of Radiology, 33, Suppl., 4, 4, 2015年02月
(公社)日本医学放射線学会, 日本語

Serial changes of hypoxia and glucose metabolism in head and neck cancer after Intensity Modulated Radiation Therapy
S. Okamoto, T. Shiga, K. Yasuda, K. Magota, K. Kasai, S. Watanabe, Y. Kuge, H. Shirato, N. Tamaki, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 41, S196, S196, 2014年10月
英語, 研究発表ペーパー・要旨（国際会議）

FMISO-PETによる低酸素と糖代謝分布の相関についての検討
渡邊 史郎, 岡本 祥三, 安田 耕一, 志賀 哲, 孫田 恵一, 葛西 克彦, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 51, 3, 265, 265, 2014年09月
(一社)日本核医学会, 日本語

Hypoxic information evaluated FMISO-PET was independent of glucose metabolic activity
Watanabe Shiro, Okamoto Shozo, Shiga Tohru, Yasuda Koichi, Magota Keiichi, Kasai Katsuhiko, Kuge Yuji, Shirato Hiroki, Tamaki Nagara, JOURNAL OF NUCLEAR MEDICINE, 55, 2014年05月, ［査読有り］

局所進行頭頸部癌に対する導入化学療法後のweekly CDDP併用化学放射線療法の安全性と有用性の検討
水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 清水 康, 秋田 弘俊, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭, 頭頸部癌, 40, 2, 177, 177, 2014年05月
(一社)日本頭頸部癌学会, 日本語

当院における下咽頭癌に対する強度変調放射線治療(IMRT)の初期経験
土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊, 頭頸部癌, 40, 2, 257, 257, 2014年05月
(一社)日本頭頸部癌学会, 日本語

下咽頭癌に対するRADPLATとweekly CDDP併用化学放射線治療の比較検討
古沢 純, 本間 明宏, 坂下 智博, 畠山 博充, 加納 里志, 水町 貴諭, 土屋 和彦, 吉田 大介, 安田 耕一, 白土 博樹, 福田 諭, 頭頸部癌, 40, 2, 198, 198, 2014年05月
(一社)日本頭頸部癌学会, 日本語

中咽頭扁平上皮癌症例に対するWeekly CDDP併用化学放射線療法の臨床的検討
水町 貴諭, 本間 明宏, 坂下 智博, 加納 里志, 畠山 博充, 土屋 和彦, 安田 耕一, 鬼丸 力也, 白土 博樹, 福田 諭, 頭頸部癌, 40, 1, 66, 70, 2014年04月
(一社)日本頭頸部癌学会, 日本語

放射線治療に関する名称付けルール
安田耕一, 土屋和彦, 井上哲也, 西岡健太郎, 原田慶一, 西川由記子, 鬼丸力也, 清水伸一, 加藤徳雄, 木下留美子, 小野寺俊介, 白土博樹, 鈴木隆介, 藤田勝久, 辻真太郎, 山崎理衣, Jpn J Radiol, 32, Supplement, 7, 2014年02月25日
日本語

放射線療法に関する名付けルール(Naming rule for radiation therapy)　　　　　　　　　　　　　　　
安田 耕一, 土屋 和彦, 井上 哲也, 西岡 健太郎, 原田 慶一, 西川 由記子, 鬼丸 力也, 清水 伸一, 加藤 徳雄, 木下 留美子, 小野寺 俊介, 白土 博樹, 鈴木 隆介, 藤田 勝久, 辻 真太郎, 山崎 理衣, Japanese Journal of Radiology, 32, Suppl., 7, 7, 2014年02月
(公社)日本医学放射線学会, 日本語

頸部転移性骨腫瘍におけるスポットスキャニング照射法を用いた陽子線治療の線量分布評価
吉村 高明, 安田 耕一, 寅松 千枝, 高尾 聖心, 松浦 妙子, 二本木 英明, 木下 留美子, 鬼丸 力也, 白土 博樹, 石川 正純, Japanese Journal of Radiology, 32, Suppl., 7, 7, 2014年02月
(公社)日本医学放射線学会, 日本語

北海道大学病院における髄膜腫に対する強度変調放射線治療(IMRT)の初期成績
西川 由記子, 原田 慶一, 西岡 健太郎, 安田 耕一, 井上 哲也, 土屋 和彦, 小野寺 俊輔, 木下 留美子, 加藤 徳雄, 清水 伸一, 鬼丸 力也, 白土 博樹, 鈴木 隆介, 石川 正純, Japanese Journal of Radiology, 32, Suppl., 5, 5, 2014年02月
(公社)日本医学放射線学会, 日本語

The Impact of FMISO-PET Before Treatment in Nasopharyngeal Cancer Patients
K. Yasuda, K. Tsuchiya, S. Okamoto, R. Onimaru, T. Shiga, K. Harada, R. Suzuki, Y. Kuge, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, 2, S644, S644, 2013年10月
英語, 研究発表ペーパー・要旨（国際会議）

頭頚部癌に対するIMRTにおける腫瘍低酸素の経時的変化
岡本祥三, 志賀哲, 安田耕一, 孫田恵一, 葛西克彦, 久下裕司, 白土博樹, 玉木長良, 核医学, 50, 3, 218, 2013年09月30日
日本語

頭頸部癌に対するIMRTにおける腫瘍低酸素の経時的変化
岡本 祥三, 志賀 哲, 安田 耕一, 孫田 恵一, 葛西 克彦, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 50, 3, S208, S208, 2013年09月
(一社)日本核医学会, 日本語

半導体PETによるがん低酸素部位の同定及び放射線治療への応用
安田耕一, Isot News, 712, 2, 6, 2013年08月01日
日本語

SU‐E‐J‐57: A Feasibility Study On Molecular‐Imaging‐Based Real‐Time Tumor Tracking for Gated Radiotherapy
M. Ishikawa, S. Tanabe, S. Yamaguchi, N. Ukon, T. Yamanaka, K. Sutherland, N. Miyamoto, R. Suzuki, N. Katoh, K. Yasuda, H. Shirato, Medical Physics, 40, 6, 162, 2013年06月

動注化学療法による化学放射線療法~上顎洞癌を中心に~
本間明宏, 畠山博充, 加納里志, 水町貴諭, 坂下智博, 吉田大介, 鬼丸力也, 土屋和彦, 安田耕一, 白土博樹, 藤井正人, 福田諭, 頭けい部癌, 39, 2, 134, 2013年05月21日
日本語

化学放射線療法の現状と役割 動注化学療法による化学放射線療法 上顎洞癌を中心に
本間 明宏, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 藤井 正人, 福田 諭, 頭頸部癌, 39, 2, 134, 134, 2013年05月
(一社)日本頭頸部癌学会, 日本語

北海道大学病院における上咽頭癌の治療 10年間(2000〜2010)のまとめ
土屋 和彦, 安田 耕一, 西川 由記子, 木下 留美子, 鬼丸 力也, 原田 慶一, 井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 西岡 健, 鈴木 恵士郎, 田口 大志, 長谷川 雅一, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭, 竹内 啓, 田口 純, 耳鼻咽喉科展望, 56, 補冊2, 174, 175, 2013年05月
耳鼻咽喉科展望会, 日本語

II-IV期上咽頭癌に対する化学放射線同時併用療法 併用化学療法に関する後ろ向き比較検討
土屋 和彦, 安田 耕一, 木下 留美子, 鬼丸 力也, 白土 博樹, 本間 明宏, 福田 諭, 清水 康, 秋田 弘俊, 頭頸部癌, 39, 2, 218, 218, 2013年05月
(一社)日本頭頸部癌学会, 日本語

当科で放射線治療を施行した頭頸部原発小細胞癌症例の検討
西川 由記子, 安田 耕一, 土屋 和彦, 鬼丸 力也, 白土 博樹, 本間 明宏, 竹内 啓, 田口 純, Japanese Journal of Radiology, 31, Suppl.I, 12, 12, 2013年02月
(公社)日本医学放射線学会, 日本語

照射前FMISO-PETの集積部位と照射後再発の位置関係
安田 耕一, 土屋 和彦, 岡本 祥三, 鬼丸 力也, 志賀 哲, 加藤 徳雄, 原田 慶一, 久下 裕司, 玉木 長良, 白土 博樹, 日本医学放射線学会学術集会抄録集, 72回, S381, S382, 2013年02月
(公社)日本医学放射線学会, 日本語

Retrospective Comparison Between Cisplatin Plus Fluorouracil and Weekly Cisplatin in Concurrent Chemoradiation Therapy Setting for Stage II-IV Nasopharyngeal Carcinoma
K. Tsuchiya, K. Yasuda, Y. Nishikawa, R. Kinoshita, R. Onimaru, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84, 3, S484, S485, 2012年11月
英語, 研究発表ペーパー・要旨（国際会議）

切除可能T3、T4上顎洞扁平上皮癌における手術の位置付け 当院における治療戦略
本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 吉田 大介, 鬼丸 力也, 土屋 和彦, 安田 耕一, 白土 博樹, 福田 諭, 耳鼻と臨床, 58, Suppl.1, S52, S56, 2012年11月
This retrospective study aimed to assess the role of salvage surgery for local recurrence after concomitant radiotherapy and superselective arterial infusion of cisplatin (RADPLAT) in patients with squamous cell carcinoma cancer of the maxillary sinus as an initial treatment. Forty-one patients were treated by RADPLAT between 1999 and 2009. Local recurrence in the primary site was observed in 12 patients of whom 9 could undergo further salvage surgery. Primary disease control was achieved in 7 of these patients (successful salvage rate, 58.3%). Successful salvage rates for T3, T4a and T4b primary disease were 66.7% (2/3), 66.7% (4/6) and 33.3% (1/3), respectively. The 5-year overall survival rate was 73.6% in all patients. Severe postoperative complication was seen in one patient. Prognosis of patients with locally recurring maxillary sinus squamous cell carcinoma after RADPLAT is relatively good. This is because residual/recurrent tumor was located in anterior portion of the face in most cases. This result should be taken into consideration when the initial treatment plan is decided and the choice of salvage surgery for such recurrent cases should be carefully determined., 耳鼻と臨床会, 日本語

当科で導入化学療法を施行した頭頸部局所進行扁平上皮癌症例の治療成績　　　　　　　　　　　　　　　
天野 虎次, 田口 純, 木下 一郎, 合田 智宏, 本間 理央, 竹内 啓, 清水 康, 安田 耕一, 土屋 和彦, 白土 博樹, 本間 明宏, 福田 諭, 秋田 弘俊, 日本癌治療学会誌, 47, 3, 2112, 2112, 2012年10月
(一社)日本癌治療学会, 日本語

頭頚部癌に対するFMISO‐PETの再現性評価
岡本祥三, 志賀哲, 安田耕一, 孫田恵一, 葛西克彦, 久下裕司, 白土博樹, 玉木長良, 核医学, 49, 3, 217, 2012年08月31日
日本語

頭頸部癌に対するFMISO-PETの再現性評価
岡本 祥三, 志賀 哲, 安田 耕一, 孫田 恵一, 葛西 克彦, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 49, 3, S197, S197, 2012年08月
(一社)日本核医学会, 日本語

低酸素イメージングと放射線治療(Hypoxia imaging and Radiation therapy)　　　　　　　　　　　　　　　
安田 耕一, 鬼丸 力也, 岡本 祥三, 志賀 哲, 加藤 徳雄, 玉木 長良, 白土 博樹, 日本癌学会総会記事, 71回, 84, 85, 2012年08月
日本癌学会, 英語

FMISO PET検査における低酸素領域の半定量 基準値としての後頸部筋と血液の比較
葛西 克彦, 岡本 祥三, 志賀 哲, 安田 耕一, 孫田 惠一, 加藤 千恵次, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 49, 3, S197, S197, 2012年08月
(一社)日本核医学会, 日本語

リンフォーマの画像診断と新規治療のプラクティス 皮膚悪性リンパ腫に対する放射線治療　　　　　　　　　　　　　　　
鬼丸 力也, 清水 伸一, 土屋 和彦, 加藤 徳雄, 木下 留美子, 井上 哲也, 小野寺 俊輔, 安田 耕一, 西岡 健太郎, 白土 博樹, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 28回, 82, 82, 2012年06月
(一社)日本皮膚悪性腫瘍学会, 日本語

先進的放射線治療におけるPETの役割
加藤徳雄, 鬼丸力也, 安田耕一, 志賀哲, 土屋和彦, 岡本祥三, 玉木長良, 白土博樹, 日本薬学会年会要旨集, 132nd, 1, 118, 118, 2012年03月05日
(公社)日本薬学会, 日本語

放射線を利用した画像診断・治療の最前線 先進的放射線治療におけるPETの役割　　　　　　　　　　　　　　　
加藤 徳雄, 鬼丸 力也, 安田 耕一, 志賀 哲, 土屋 和彦, 岡本 祥三, 玉木 長良, 白土 博樹, 日本薬学会年会要旨集, 132年会, 1, 118, 118, 2012年03月
(公社)日本薬学会, 日本語

頭頚部癌の放射線治療前後におけるFMISO集積の初期経過
岡本祥三, 竹井俊樹, 志賀哲, 玉木長良, 安田耕一, 白土博樹, 久下裕司, 森本裕一, 竹内渉, Jpn J Radiol, 30, Supplement 1, 7, 2012年02月25日
日本語

頭頸部癌の放射線治療前後におけるFMISO集積の初期経過　　　　　　　　　　　　　　　
岡本 祥三, 竹井 俊樹, 志賀 哲, 玉木 長良, 安田 耕一, 白土 博樹, 久下 裕司, 森本 裕一, 竹内 渉, Japanese Journal of Radiology, 30, Suppl.I, 7, 7, 2012年02月
(公社)日本医学放射線学会, 日本語

胃MALTリンパ腫に対する動体追跡照射の経験
米山 理奈, 安田 耕一, 加藤 徳雄, 鬼丸 力也, 白土 博樹, Japanese Journal of Radiology, 30, Suppl.I, 5, 5, 2012年02月
(公社)日本医学放射線学会, 日本語

上咽頭癌再発症例に対する再照射例の検討
鬼丸 力也, 安田 耕一, 西川 昇, 米山 理奈, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭, Japanese Journal of Radiology, 30, Suppl.I, 5, 5, 2012年02月
(公社)日本医学放射線学会, 日本語

声門癌(T1N0)に対する北大病院での放射線治療成績
鬼丸 力也, 白土 博樹, 安田 耕一, 長谷川 雅一, Japanese Journal of Radiology, 30, Suppl.I, 13, 13, 2012年02月
(公社)日本医学放射線学会, 日本語

マルチベンダに対応した放射線治療計画管理システムの開発
辻 真太朗, 鈴木 隆介, 安田 耕一, 藤田 勝久, 宮崎 智夫, 石川 正純, 白土 博樹, 日本放射線技術学会総会学術大会予稿集, 68回, 134, 134, 2012年02月
(公社)日本放射線技術学会, 日本語

胃悪性リンパ腫に対する迎撃照射とマーカー移動の解析
加藤 徳雄, 鈴木 隆介, 井上 哲也, 安田 耕一, 鬼丸 力也, 清水 伸一, 木村 理奈, 石川 正純, 白土 博樹, 日本医学放射線学会学術集会抄録集, 71回, S316, S316, 2012年02月
(公社)日本医学放射線学会, 日本語

Real-time Tumor-tracking Radiation Therapy for Lymphoma of the Stomach
Katoh N, Suzuki R, Shimizu S, Inoue T, Yasuda K, Onimaru R, Kimura R, Kato M, Ishikawa M, Shirato H, International Journal of Radiation Oncology Biology Physics, 84, 3, S722, 2012年, ［査読有り］

当院で施行した頭頚部局所進行扁平上皮癌に対するDCF(docetaxel,cisplatin,5‐FU)導入化学療法の検討
田口純, 天野虎次, 木下一郎, 合田智宏, 本間理央, 竹内啓, 清水康, 安田耕一, 土屋和彦, 鬼丸力也, 本間明宏, 福田諭, 秋田弘俊, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 179, 180, 2012年
日本語

当科で導入化学療法を施行した頭頚部局所進行扁平上皮癌症例の治療成績
天野虎次, 田口純, 木下一郎, 合田智宏, 本間理央, 竹内啓, 清水康, 安田耕一, 土屋和彦, 白土博樹, 本間明宏, 福田諭, 秋田弘俊, 日本癌治療学会学術集会(CD-ROM), 50th, 3, ROMBUNNO.PS2-008, 2112, 2012年
(一社)日本癌治療学会, 日本語

食道癌IMRT(強度変調放射線治療)の初期経験
原田 慶一, 井上 哲也, 安田 耕一, 加藤 徳雄, 清水 伸一, 白土 博樹, Bengua Gerard, 石川 正純, 中積 宏之, 結城 敏志, 小松 嘉人, 北海道外科雑誌, 56, 2, 176, 177, 2011年12月
北海道外科学会, 日本語

頭頸部癌の放射線治療前後におけるFMISO集積の初期経過
岡本 祥三, 竹井 俊樹, 志賀 哲, 玉木 長良, 安田 耕一, 白土 博樹, 久下 裕司, 森本 裕一, 竹内 渉, 核医学, 48, 4, 436, 436, 2011年11月
(一社)日本核医学会, 日本語

放射線療法の進歩と将来展望 放射線治療におけるPositron emission tomography(PET)検査の利用
鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 岡本 祥三, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌, 37, 3, 376, 380, 2011年10月
(一社)日本頭頸部癌学会, 日本語

頭頚部癌に対する放射線治療経過における低酸素と糖代謝の変化
岡本祥三, 安田耕一, 志賀哲, 竹井俊樹, 孫田恵一, 久下裕司, 白土博樹, 玉木長良, 核医学, 48, 3, 344, 2011年09月30日
日本語

頭頸部癌に対する放射線治療経過における低酸素と糖代謝の変化
岡本 祥三, 安田 耕一, 志賀 哲, 竹井 俊樹, 孫田 恵一, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 48, 3, S282, S282, 2011年09月
(一社)日本核医学会, 日本語

放射線治療におけるPETの利用
鬼丸力也, 安田耕一, 加藤徳男, 白土博樹, 志賀哲, 玉木長良, 本間明宏, 折舘伸彦, 福田諭, 頭けい部癌, 37, 2, 185, 2011年05月20日
日本語

上咽頭癌患者における放射線療法のFMISO PETとアウトカムとの相関
安田耕一, 岡本祥三, 志賀哲, 鬼丸力也, 長谷川雅一, 久下裕司, 竹内渉, 梅垣菊男, 玉木長良, 白土博樹, 頭けい部癌, 37, 2, 256, 2011年05月20日
日本語

放射線治療の進歩と将来展望 放射線治療におけるPETの利用
鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌, 37, 2, 185, 185, 2011年05月
(一社)日本頭頸部癌学会, 日本語

FMISO PETと上咽頭癌患者に対する放射線療法の成績の相関性(Correlation of FMISO PET and outcome from radiation therapy in patients with nasopharyngeal cancer)
安田 耕一, 岡本 祥三, 志賀 哲, 鬼丸 力也, 長谷川 雅一, 久下 裕司, 竹内 渉, 梅垣 菊男, 玉木 長良, 白土 博樹, 頭頸部癌, 37, 2, 256, 256, 2011年05月
(一社)日本頭頸部癌学会, 日本語

頭頸部進行癌に対する集学的治療 "導入化学療法→化学放射線同時併用療法"
本間 明宏, 清水 康, 折舘 伸彦, 鬼丸 力也, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 安田 耕一, 秋田 弘俊, 白土 博樹, 福田 諭, 頭頸部癌, 37, 2, 233, 233, 2011年05月
(一社)日本頭頸部癌学会, 日本語

頭頸部扁平上皮癌N+症例における放射線動注化学療法後の頸部評価 Wait and See Policyは成立するか
坂下 智博, 本間 明宏, 折舘 伸彦, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹, 頭頸部癌, 37, 2, 231, 231, 2011年05月
(一社)日本頭頸部癌学会, 日本語

Prospective Study on the Effect of High Resolution Semiconductor PET in Fluoromisonidazole (FMISO)-Guided Intensity Modulated Radiation Therapy (IMRT) Dose-escalation Simulation Planning in Patients with Nasopharyngeal Carcinoma (NPC)
K. Yasuda, S. Okamoto, R. Onimaru, T. Shiga, M. Hasegawa, N. Katoh, Y. Kuge, K. Umegaki, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2, S506, S507, 2011年
英語, 研究発表ペーパー・要旨（国際会議）

放射線治療におけるＰｏｓｉｔｒｏｎ ｅｍｉｓｓｉｏｎ ｔｏｍｏｇｒａｐｈｙ（ＰＥＴ）検査の利用
鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 岡本 祥三, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌, 37, 3, 376, 380, 2011年
Japan Society for Head and Neck Cancer, 日本語

放射線治療における Positron emission tomography (PET) 検査の利用
鬼丸 力也, 安田 耕一, 加藤 徳男, 白土 博樹, 志賀 哲, 岡本 祥三, 玉木 長良, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌 = Head and neck cancer, 37, 3, 376, 380, 2011年
日本語

頭頸部リンパ節腫瘍における放射線治療効果予測
高尾聖心, 但野茂, 田口大志, 安田耕一, 鬼丸力也, 石川正純, 鈴木隆介, GERARD Bengua, 白土博樹, 日本生体医工学会大会プログラム・論文集(CD-ROM), 50th, ROMBUNNO.O1-9-5, 2011年
日本語

巨大リンパ節転移を伴う上咽頭癌の一例
西川 昇, 長谷川 雅一, 安田 耕一, 鬼丸 力也, 白土 博樹, Japanese Journal of Radiology, 29, Suppl.I, 5, 5, 2011年01月
(公社)日本医学放射線学会, 日本語

頭頚部癌の放射線治療前後におけるFMISO集積の初期経過
岡本祥三, 安田耕一, 安田耕一, 竹井俊樹, 志賀哲, 久下裕司, 久下裕司, 白土博樹, 白土博樹, 玉木長良, 核医学, 47, 3, S220, 2010年09月30日
日本語

頭頸部癌の放射線治療前後におけるFMISO集積の初期経過
岡本 祥三, 安田 耕一, 竹井 俊樹, 志賀 哲, 久下 裕司, 白土 博樹, 玉木 長良, 核医学, 47, 3, 374, 374, 2010年09月
(一社)日本核医学会, 日本語

H&N癌のための18F‐フルオロミソニダゾールPETの影響とIMRTへの適用
安田耕一, 長谷川雅一, 鬼丸力也, 木下留美子, 加藤徳雄, 田口大志, 清水伸一, 井上哲也, 小野寺俊輔, 溝口史樹, 青山英史, 白土博樹, 志賀哲, 岡本祥三, 玉木長良, 石川正純, SUTHERLAND Kenneth, BENGUA Gerard, 宮本直樹, 鈴木隆介, Jpn J Radiol, 28, Supplement 1, 14, 2010年07月25日
日本語

H&N癌に対する18F-fluoromisonidazole PETの有用性とIMRTへの応用(The impact of 18F-fluoromisonidazole PET for H&N cancer and the applying for IMRT)　　　　　　　　　　　　　　　
安田 耕一, 長谷川 雅一, 鬼丸 力也, 木下 留美子, 加藤 徳雄, 田口 大志, 清水 伸一, 井上 哲也, 小野寺 俊輔, 溝口 史樹, 青山 英史, 白土 博樹, 志賀 哲, 岡本 祥三, 玉木 長良, 石川 正純, Sutherland Kenneth, Bengua Gerard, 宮本 直樹, 鈴木 隆介, Japanese Journal of Radiology, 28, Suppl.I, 14, 14, 2010年07月
(公社)日本医学放射線学会, 日本語

鼻腔・副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法
長谷川 雅一, 安田 耕一, 吉田 大介, 加藤 徳雄, 鬼丸 力也, 浅野 剛, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭, 石川 正純, Bengua Gerard, Sutherland Kenneth, 宮本 直樹, 鈴木 隆介, Japanese Journal of Radiology, 28, Suppl.I, 7, 7, 2010年07月
(公社)日本医学放射線学会, 日本語

口唇癌の放射線治療のretrospective study
香泉 和寿, 安田 耕一, 長谷川 雅一, 鬼丸 力也, 清水 伸一, 木下 留美子, 井上 哲也, 加藤 徳雄, 小野寺 俊輔, 田口 大志, 溝口 史樹, 青山 英史, 白土 博樹, 西岡 健, 武島 嗣英, Japanese Journal of Radiology, 28, Suppl.I, 7, 7, 2010年07月
(公社)日本医学放射線学会, 日本語

Experimental MR imaging of zirconia ceramic joint implants at 1.5 and 3 T
T. Kamishima, N. Kitamura, M. Amemiya, K. Ishizaka, F. Kato, K. Yasuda, H. Shirato, S. Terae, CLINICAL RADIOLOGY, 65, 5, 387, 390, 2010年05月
英語

化学放射線治療後の頸部郭清の必要性について
本間 明宏, 折舘 伸彦, 鈴木 章之, 鈴木 清護, 原 敏浩, 加納 里志, 水町 貴諭, 古沢 純, 稲村 直哉, 福田 諭, 吉田 大介, 鬼丸 力也, 安田 耕一, 白土 博樹, 頭頸部癌, 36, 2, 191, 191, 2010年05月
(一社)日本頭頸部癌学会, 日本語

頭頸部癌に対するweekly cisplatinと放射線同時併用療法の検討
稲村 直哉, 本間 明宏, 折舘 伸彦, 鈴木 清護, 鈴木 章之, 原 敏浩, 真栄田 裕行, 加納 里志, 水町 貴諭, 福田 諭, 鬼丸 力也, 長谷川 雅一, 安田 耕一, 白土 博樹, 頭頸部癌, 36, 2, 206, 206, 2010年05月
(一社)日本頭頸部癌学会, 日本語

頭頸部原発・髄外性形質細胞腫に対する放射線治療成績の多施設調査研究
佐々木 良平, 安田 耕一, 阿部 栄輔, 内田 伸江, 河島 光彦, 芝本 雄太, 加賀美 芳和, 塩山 善之, 宇野 隆, 中田 健生, 冨士原 将之, 高田 佳江, 頭頸部癌, 36, 2, 212, 212, 2010年05月
(一社)日本頭頸部癌学会, 日本語

強度変調放射線治療(IMRT)の中長期成績 北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績
鬼丸 力也, 長谷川 雅一, 安田 耕一, 木下 留美子, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌, 35, 3, 245, 249, 2009年10月
(一社)日本頭頸部癌学会, 日本語

頭頚部原発・髄外性形質細胞腫に対する放射線治療成績の多施設調査研究
佐々木良平, 河辺哲也, 阿部英輔, 内田伸江, 安田耕一, 宇野隆, 冨士原雅之, 塩山善之, 芝本雄太, 山田章吾, 日本放射線腫よう学会誌, 21, Supplement 1, 136, 2009年08月19日
日本語

【機能温存をめざした頭頸部癌治療update】強度変調放射線治療(intensity modulated radiotherapy;IMRT)
鬼丸 力也, 木下 留美子, 長谷川 雅一, 安田 耕一, 白土 博樹, ENTONI, 103, 14, 20, 2009年06月
(株)全日本病院出版会, 日本語

北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績
鬼丸力也, 長谷川雅一, 安田耕一, 木下留美子, 白土博樹, 本間明宏, 折舘伸彦, 福田諭, 頭けい部癌, 35, 2, 65, 249, 2009年05月20日
2002年5月から2007年12月までに北大病院放射線科にて強度変調放射線治療（Intensity modulated radiation therapy, IMRT）を行った37例を検討した。上咽頭13例，中咽頭19例，下咽頭3例，上顎1例，口腔1例であった。<br>死亡は4例で認められた。治療終了後4ヶ月で中咽頭癌（後壁T3N0）が咽頭膿瘍後の誤嚥性肺炎で死亡したが，他の3名は他癌死であった。原発・頸部リンパ節残存・再発は，上咽頭癌で原発巣再発1例，中咽頭癌では原発巣再発が3例，頸部リンパ節転移・残存が2名，下咽頭癌では 1例で頸部リンパ節残存があった。<br>重篤な晩期反応は，中咽頭後壁の1名で咽頭膿瘍の発生による死亡があり，1例の上咽頭癌症例（CDDP併用）で聴力低下と偶角閉塞がみられた。, Japan Society for Head and Neck Cancer, 日本語

強度変調放射線治療(IMRT)の中長期成績 北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績
鬼丸 力也, 長谷川 雅一, 安田 耕一, 木下 留美子, 白土 博樹, 本間 明宏, 折舘 伸彦, 福田 諭, 頭頸部癌, 35, 2, 65, 65, 2009年05月
(一社)日本頭頸部癌学会, 日本語

上咽頭癌に対するCDDP、5-FUを用いた放射線化学療法の治療成績
木下 留美子, 長谷川 雅一, 安田 耕一, 田口 大志, 鬼丸 力也, 土屋 和彦, 西岡 健, 本間 明宏, 折舘 伸彦, 福田 諭, 白土 博樹, 頭頸部癌, 35, 2, 93, 93, 2009年05月
(一社)日本頭頸部癌学会, 日本語

¹⁸F‐FMISO PETを用いたIMRT dose painting planの試み
安田耕一, 白土博樹, 岡本祥三, 志賀哲, SUTHERLAND Ken, 加藤徳雄, 長谷川雅一, 鬼丸力也, BENGUA Gerard, 石川正純, 日本医学放射線学会総会抄録集, 68th, S267, 2009年02月28日
日本語

18F-FMISO PETを用いたIMRT dose painting planの試み　　　　　　　　　　　　　　　
安田 耕一, 白土 博樹, 岡本 祥三, 志賀 哲, Sutherland Ken, 加藤 徳雄, 長谷川 雅一, 鬼丸 力也, Bengua Gerard, 石川 正純, 日本医学放射線学会学術集会抄録集, 68回, S267, S267, 2009年02月
(公社)日本医学放射線学会, 日本語

上咽頭癌における半導体PET画像を用いた放射線治療計画
加藤 徳雄, 志賀 哲, 長谷川 雅一, 鬼丸 力也, 安田 耕一, 清水 伸一, ベングア・ジェラード, 石川 正純, 玉木 長良, 白土 博樹, 日本医学放射線学会学術集会抄録集, 68回, S307, S308, 2009年02月
(公社)日本医学放射線学会, 日本語

北海道大学病院での頭頸部癌に対する強度変調放射線治療の成績
鬼丸力也, 長谷川雅一, 安田耕一, 木下留美子, 白土博樹, 本間明宏, 折舘伸彦, 福田諭, 頭けい部癌, 35, 3, 245, 249, 2009年
日本語

鼻腔/副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法の治療成績
長谷川雅一, 安田耕一, 吉田大介, 加藤徳雄, 鬼丸力也, 浅野剛, 白土博樹, 本間明宏, 折館伸彦, 福田諭, 日本放射線腫よう学会誌, 20, Supplement 1, 223, 2008年09月22日
日本語

北海道大学における非小細胞肺癌に対する体幹部定位放射線治療の治療成績
鬼丸力也, 加藤徳雄, 井上哲也, 田口大志, 清水伸一, 長谷川雅一, 安田耕一, 小野寺俊輔, 木下留美子, 青山英史, 白土博樹, 日本放射線腫よう学会誌, 20, Supplement 1, 128, 2008年09月22日
日本語

Skull base MeningiomaにおけるIMRTの利用 当院治療成績を踏まえて
小野寺 俊輔, 白土 博樹, 青山 英史, 田口 大志, 加藤 徳雄, 木下 留美子, 鬼丸 力也, 清水 伸一, 井上 哲也, 安田 耕一, 日本医学放射線学会秋季臨床大会抄録集, 44回, S521, S521, 2008年09月
(公社)日本医学放射線学会, 日本語

切除不能膵臓癌に対する強度変調放射線治療(IMRT)に向けての基礎的研究
安田 耕一, Radiation Medicine, 26, Suppl.I, 5, 5, 2008年04月
(公社)日本医学放射線学会, 日本語

当院における遠隔放射線治療の現状について
鈴木 恵士郎, 木下 留美子, 鬼丸 力也, 安田 耕一, 小野寺 俊介, 加藤 徳雄, 田口 大志, 藤野 賢治, 青山 英史, 白土 博樹, 宮坂 和男, Radiation Medicine, 26, Suppl.I, 3, 3, 2008年04月
(公社)日本医学放射線学会, 日本語

動態追跡照射時の肺腫瘍の動きに関連する因子の検討
小野寺 祐也, 西岡 典子, 安田 耕一, 藤間 憲幸, 鬼丸 力也, 清水 伸一, 白土 博樹, 日本医学放射線学会学術集会抄録集, 67回, S193, S193, 2008年02月
(公社)日本医学放射線学会, 日本語

【脊椎脊髄病変に対する最新の放射線治療】脊椎脊髄病変に対する強度変調放射線治療(IMRT)
溝口 史樹, 安田 耕一, 青山 英史, 白土 博樹, 脊椎脊髄ジャーナル, 20, 7, 781, 785, 2007年07月
(株)三輪書店, 日本語

胆嚢粘液癌の一例
安田 耕一, Radiation Medicine, 25, Suppl.I, 30, 30, 2007年04月
(公社)日本医学放射線学会, 日本語

多発肺腫瘍に対する3ケ月以内の連続した定位照射の安全性と有効性の検討
鬼丸力也, 藤野賢治, 田口大志, 加藤徳雄, 木下留美子, 安田耕一, 鈴木恵士郎, 白土博樹, 宮坂和男, 日本医学放射線学会学術集会抄録集, 66th, S233, 2007年02月28日
日本語

多発肺腫瘍に対する3ヵ月以内の連続した定位照射の安全性と有効性の検討　　　　　　　　　　　　　　　
鬼丸 力也, 藤野 賢治, 田口 大志, 加藤 徳雄, 木下 留美子, 安田 耕一, 鈴木 恵士郎, 白土 博樹, 宮坂 和男, 日本医学放射線学会学術集会抄録集, 66回, S233, S233, 2007年02月
(公社)日本医学放射線学会, 日本語

Low-dose craniospinal irradiation (CSI) with computed tomographic (CT) simulation and ifosfamide, cisplatin, and etopiside for non-metastatic embryonal tumors in the central nervous system
H. Taguchi, K. Yasuda, H. Aoyama, Y. Sawamura, J. Ikeda, K. Fujieda, Y. Iwasaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69, 3, S241, S241, 2007年
英語, 研究発表ペーパー・要旨（国際会議）

【胸部の最新画像情報2007】CT FDG-PET fusion imageの肺癌放射線治療計画への利用
藤野 賢治, 田口 大志, 加藤 徳雄, 青山 英史, 鈴木 恵士郎, 鬼丸 力也, 木下 留美子, 安田 耕一, 白土 博樹, 加藤 知恵次, 志賀 哲, 玉木 長良, 小野寺 俊輔, 臨床放射線, 52, 1, 137, 144, 2007年01月
金原出版(株), 日本語

Utilization the fusion image of CT and FDG-PET for radiation therapy planning in lung cancer
Masaharu Fujino, T. Taguchi, T. Kato, H. Aoyama, K. Suzuki, R. Onimaru, R. Kinoshita, K. Yasuda, H. Shirato, C. Kato, S. Shiga, N. Tamaki, S. Onodera, Japanese Journal of Clinical Radiology, 52, 1, 137, 144, 2007年

CT FDG‐PET fusion imageの肺癌放射線治療計画への利用
藤野賢治, 田口大志, 加藤徳雄, 青山英史, 鈴木恵士郎, 鬼丸力也, 木下留美子, 安田耕一, 白土博樹, 加藤知恵次, 志賀哲, 玉木長良, 小野寺俊輔, 臨床放射線, 52, 1, 137, 144, 2007年
日本語

膵癌に対する4次元強度変調放射線治療(4D‐IMRT)に向けての基礎的研究
安田耕一, 加藤徳雄, 青山英史, 田口大志, 藤野賢治, 木下留美子, 鬼丸力也, 鈴木恵士朗, 白土博樹, 宮坂和男, 日本放射線腫よう学会誌, 18, Supplement 1, 170, 2006年10月25日
日本語

医学部医学科 放射線医学　　　　　　　　　　　　　　　
2020年04月 - 現在

保健学科 放射線腫瘍学　　　　　　　　　　　　　　　
2014年04月 - 現在

医理工学院 放射線生物学　　　　　　　　　　　　　　　
2017年04月 - 2020年03月

医理工学院 医療機器研究　　　　　　　　　　　　　　　
2017年04月 - 2020年03月

放射線治療科　　　　　　　　　　　　　　　
北海道大学病院

高齢頭頸部がん患者における化学放射線療法のランダム化比較試験　　　　　　　　　　　　　　　
革新的がん医療実用化研究事業
2025年10月
日本医療研究開発機構（AMED）, 研究分担者

早期非小細胞肺癌に対する体幹部定位放射線治療線量増加ランダム化比較試験(JCOG1408)　　　　　　　　　　　　　　　
革新的がん医療実用化研究事業
2025年04月
日本医療研究開発機構（AMED）, 研究分担者

頭頸部癌に対する適応短期放射線治療による腫瘍内⾼線量ブーストの安全性及び有効性評価のための第Ⅰ/Ⅱ相試験　　　　　　　　　　　　　　　
特定臨床研究⽀援強化事業
2024年04月 - 2025年03月
安田耕一
北海道大学病院, 研究代表者

陽子線治療の高精度技術標準化に基づいたモデルアプローチを含む臨床的有効性確立に関する研究　　　　　　　　　　　　　　　
国立がん研究センター研究開発費
2023年04月 - 2025年03月
国立がん研究センター, 研究分担者

頭頸部癌に対する定位的及び適応放射線治療による腫瘍内高線量ブースト試験　　　　　　　　　　　　　　　
医師主導治験及び特定臨床研究実施に係る加速化に向けた研究支援プログラム / スタートアップ支援事業
2023年04月 - 2024年03月
安田耕一
北海道大学病院, 北海道大学病院, 研究代表者

IMPTを用いた「辛くない」頭頸部癌放射線治療法の開発
科学研究費助成事業 基盤研究(C)
2019年04月 - 2023年03月
安田 耕一, 加納 里志, 水町 貴諭, 高尾 聖心, 田村 昌也
後ろ向き観察研究の自主臨床計画書を作成し、当施設の審査会にて承認された。
スポットスキャニングIMPTにおける皮膚、唾液腺、舌、粘膜の線量を大幅に低減させる手法の開発に取り組んだ。皮膚に関しては当院で過去に実施された放射線治療患者の線量分布および皮膚炎の程度を解析し、皮膚炎発症に最も関連する皮膚線量のパラメーターを解析した。DVH(dose-volume histogram)解析において、皮膚のV65Gy（65Gy以上照射される皮膚の体積）が皮膚炎グレード3発症に関連する独立因子であることを突き止めた。皮膚炎発症と線量に関するモデル作成について検討を開始した。スポットスキャニングIMPTにおいて、局所的な皮膚線量を低減するプランニング法の開発を開始した。耳下腺及び舌に関しても同様に、線量低減のプランニング法の開発を開始した。粘膜線量低減のために、頭頸部癌におけるPTV(planning target volume) margin（照射ターゲットの位置の不確かさのために付与するマージン）の検証を行った。照射中に撮像可能なCBCT（cone-beam CT）を用いて照射前後の頭頸部の各領域の動きの変化を検証した。各領域に最適なPTV marginを個別に付与する（variable PTV marginの設定）方法の基礎的知見を得た。従来の放射線治療法で治療された頭頸部癌患者に対しQOL調査を行った。四大副作用、つまり皮膚炎、口渇、味覚障害、粘膜炎に関して、患者が感じる「辛さ」を客観的に把握するための調査項目を決定し、調査を開始した。
日本学術振興会, 基盤研究(C), 北海道大学, 研究代表者, 19K08088

低酸素癌を標的とした陽子線治療に関する研究
科学研究費助成事業
2016年04月 - 2019年03月
安田 耕一, 西川 由記子
低酸素癌を標的としたスポットスキャニング陽子線治療のシミュレーョンを行う環境を構築した。10例の上咽頭癌患者において、低酸素癌を標的としたスポットスキャニング陽子線治療装置によるintensity-modulated proton therapy (IMPT)のシミュレーションを行い、X線によるintensity-modulated X-ray therapy (IMXT)と比較したところ、耳下腺や口腔の線量及び障害発生確率は陽子線治療の方が低い値であった。低酸素を標的とした放射線治療を実施する際に、スポットスキャニング陽子線治療がX線よりも有用であることを示した。
日本学術振興会, 若手研究(B), 北海道大学, 16K19797

頭頸部扁平上皮癌に対する強度変調陽子線治療の実用化に向けた技術開発と有効性検証　　　　　　　　　　　　　　　
革新的がん医療実用化研究事業
2017年04月
本医療研究開発機構（AMED）, 研究分担者

癌に対する線量増加放射線治療の理論確立:FMISO-PETを用いた再酸素化の証明　　　　　　　　　　　　　　　
科学研究費補助金(基盤研究(C))
2013年 - 2015年
岡本 祥三
研究分担者 安田耕一
文部科学省, 競争的資金

低酸素癌細胞に対する放射線治療～生物学的に最適な線量投与法の確立～
科学研究費補助金(若手研究(B))
2013年 - 2015年
安田 耕一
基礎実験において低酸素癌細胞は放射線治療抵抗性とされるが、臨床での意義ははっきりしない。治療前に撮像された低酸素イメージングであるFMISO-PETの集積部位と、放射線治療後の再発部位との位置関係が解析された。1 x 1 x 2mmの小さなボクセル単位での解析において、再発患者では治療前のFMISO集積が強い部位に再発をきたしやすい事が明らかとなった。また、FMISO-PETの強い集積の部分に、高い線量を投与する放射線治療シミュレーションの方法が研究された。この研究の一部は、放射線治療世界最高峰の学会である米国放射線腫瘍学会に演題採択され、結果が公表された。
文部科学省, 若手研究(B), 北海道大学, 研究代表者, 競争的資金, 25861046

治療実績評価支援装置、治療実績評価支援方法、および治療実績評価支援プログラム
特許権, 白土 博樹, 上杉 正人, 安田 耕一, 熊木 康雄, 三浦 孝豊, 苧野 博司, 株式会社ジェイマックシステム, 国立大学法人北海道大学
特願2017-042366, 2017年03月07日
特開2018-147275, 2018年09月20日
特許第6940088号, 2021年09月06日
202103015621186076

医用画像情報システム、医用画像情報処理方法及びプログラム
特許権, 松崎 和喜, 森本 裕一, 竹内 渉, 梅垣 菊男, 志賀 哲, 安田 耕一, 株式会社日立製作所
特願2014-090139, 2014年04月24日
特開2015-208385, 2015年11月24日
特許第6220310号, 2017年10月06日
2017年10月06日
201703019383159939